issuerCik,issuerName,issuerTradingSymbol,reportingOwnerId.rptOwnerCik,reportingOwnerId.rptOwnerName,reportingOwnerAddress.rptOwnerStreet1,reportingOwnerAddress.rptOwnerStreet2,reportingOwnerAddress.rptOwnerCity,reportingOwnerAddress.rptOwnerState,reportingOwnerAddress.rptOwnerZipCode,reportingOwnerAddress.rptOwnerStateDescription,reportingOwnerRelationship.isDirector,reportingOwnerRelationship.isOfficer,reportingOwnerRelationship.isTenPercentOwner,reportingOwnerRelationship.isOther,reportingOwnerRelationship.officerTitle,reportingOwnerRelationship.otherText,footnote_,transactionDate
0001348036,"AVALARA, INC.",AVLR,0001034604,SHARPLES BRIAN,255 SOUTH KING ST.,SUITE 1800,SEATTLE,WA,98104,,1,0,0,0,,,"id=""F1"">The option vests and becomes exercisable in full on the earlier to occur of June 11, 2021, or the date immediately prior to the date of the 2021 annual meeting of the Issuer's shareholders.",2020-06-11
0000104169,Walmart Inc.,WMT,0001013440,WALTON ALICE L,P.O. BOX 1860,,BENTONVILLE,AR,72712,,,,1,,,,"id=""F1"">This sale from the Walton Family Holdings Trust (the ""Trust"") was executed in multiple trades at prices ranging from $149.39 to $150.39, inclusive.  The price reported above reflects the weighted average sale price.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.",2020-11-23
0000104169,Walmart Inc.,WMT,0001013440,WALTON ALICE L,P.O. BOX 1860,,BENTONVILLE,AR,72712,,,,1,,,,"id=""F2"">This sale from the Trust was executed in multiple trades at prices ranging from $150.40 to $151.40, inclusive.  The price reported above reflects the weighted average sale price.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.",2020-11-23
0000104169,Walmart Inc.,WMT,0001013440,WALTON ALICE L,P.O. BOX 1860,,BENTONVILLE,AR,72712,,,,1,,,,"id=""F3"">On November 24, 2020, the reporting person made a charitable gift of 650,000 shares of Common Stock.",2020-11-23
0000104169,Walmart Inc.,WMT,0001013440,WALTON ALICE L,P.O. BOX 1860,,BENTONVILLE,AR,72712,,,,1,,,,"id=""F4"">This sale from the Trust was executed in multiple trades at prices ranging from $151.815 to $151.97, inclusive.  The price reported above reflects the weighted average sale price.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and prices at which the transaction was effected.",2020-11-23
0000104169,Walmart Inc.,WMT,0001013440,WALTON ALICE L,P.O. BOX 1860,,BENTONVILLE,AR,72712,,,,1,,,,"id=""F5"">The reporting person is a trustee of the Trust, the entity that holds 387,242,468 shares of Common Stock.  The reporting person disclaims beneficial ownership of the reported securities held by the Trust except to the extent of her pecuniary interest therein.",2020-11-23
0000104169,Walmart Inc.,WMT,0001013440,WALTON ALICE L,P.O. BOX 1860,,BENTONVILLE,AR,72712,,,,1,,,,"id=""F6"">The reporting person is a member of Walton Enterprises, LLC, the entity that owns 1,000,891,131 shares of Common Stock.  The reporting person disclaims beneficial ownership of the reported securities held by such LLC except to the extent of her pecuniary interest therein.",2020-11-23
0001049521,MERCURY SYSTEMS INC,MRCY,0001211771,THIBAUD DIDIER M C,50 MINUTEMAN ROAD,,ANDOVER,MA,01810,,false,true,false,false,"EVP, COO",,"id=""F1"">Pursuant to a 10b5-1 stock trading plan established on January 31, 2020.",2020-03-02
0001049521,MERCURY SYSTEMS INC,MRCY,0001211771,THIBAUD DIDIER M C,50 MINUTEMAN ROAD,,ANDOVER,MA,01810,,false,true,false,false,"EVP, COO",,"id=""F2"">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.16, inclusive.",2020-03-02
0001049521,MERCURY SYSTEMS INC,MRCY,0001211771,THIBAUD DIDIER M C,50 MINUTEMAN ROAD,,ANDOVER,MA,01810,,false,true,false,false,"EVP, COO",,"id=""F3"">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.26 to $79.48 inclusive.",2020-03-02
0001712184,Liberty Latin America Ltd.,LILA,0001058725,FRIES MICHAEL T,1550 WEWATTA STREET,SUITE 710,DENVER,CO,80202,,1,1,0,0,Executive Chairman,,"id=""F1"">The rights offering is subject to termination or extension by the Issuer at any time prior to consummation.",2020-09-22
0001712184,Liberty Latin America Ltd.,LILA,0001058725,FRIES MICHAEL T,1550 WEWATTA STREET,SUITE 710,DENVER,CO,80202,,1,1,0,0,Executive Chairman,,"id=""F2"">The rights offering commenced on September 11, 2020.",2020-09-22
0001712184,Liberty Latin America Ltd.,LILA,0001058725,FRIES MICHAEL T,1550 WEWATTA STREET,SUITE 710,DENVER,CO,80202,,1,1,0,0,Executive Chairman,,"id=""F3"">The rights offering will expire at 5:00 p.m., New York City time, on September 25, 2020 unless extended by the Issuer.",2020-09-22
0001084991,NATURAL GAS SERVICES GROUP INC,NGS,0001316004,Taylor Stephen Charles,404 VETERANS AIRPARK LANE,SUITE 300,MIDLAND,TX,79705,,1,1,0,0,Chief Executive Officer,,"id=""F1"">The acquisition reflects an award of Restricted Stock pursuant to the Company's 2019 Equity Incentive Plan. The award vests in one-third annual increments beginning on the first anniversary of the grant date, subject to accelerated vesting under certain circumstances.",2020-04-28
0001084991,NATURAL GAS SERVICES GROUP INC,NGS,0001316004,Taylor Stephen Charles,404 VETERANS AIRPARK LANE,SUITE 300,MIDLAND,TX,79705,,1,1,0,0,Chief Executive Officer,,"id=""F2"">Not Applicable. The acquisition reflects an award of Restricted Stock Units (""RSU"") pursuant to the Company's 2019 Equity Incentive Plan. Each RSU represents the right to receive one share of Company common stock upon vesting.  The award vests in one-third annual increments beginning on the first anniversary of the grant date, subject to accelerated vesting under certain circumstances.",2020-04-28
0001109354,BRUKER CORP,BRKR,0001675108,Friend Cynthia M,BRUKER CORPORATION,40 MANNING ROAD,BILLERICA,MA,01821,,1,0,0,0,,,"id=""F1"">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.",2020-09-21
0001109354,BRUKER CORP,BRKR,0001675108,Friend Cynthia M,BRUKER CORPORATION,40 MANNING ROAD,BILLERICA,MA,01821,,1,0,0,0,,,"id=""F2"">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $37.79, inclusive. The reporting person undertakes to provide to Bruker Corporation, any security holder of Bruker Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.",2020-09-21
0001109354,BRUKER CORP,BRKR,0001675108,Friend Cynthia M,BRUKER CORPORATION,40 MANNING ROAD,BILLERICA,MA,01821,,1,0,0,0,,,"id=""F3"">The option vested in three approximately equal annual installments on May 20, 2017, 2018 and 2019.",2020-09-21
0001757898,STERIS plc,STE,0001136554,LEWIS DAVID B,C/O 70 SIR JOHN ROGERSON'S QUAY,,DUBLIN,L2,2,IRELAND,1,0,0,0,,,"id=""F1"">Price reflects a weighted average sale price for multiple transactions ranging from $193.75 to $193.8033 per share, inclusive.  The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.",2020-12-01
0001757898,STERIS plc,STE,0001136554,LEWIS DAVID B,C/O 70 SIR JOHN ROGERSON'S QUAY,,DUBLIN,L2,2,IRELAND,1,0,0,0,,,"id=""F2"">This option is part of an option to purchase 3,121 STERIS ordinary shares, which is fully vested, which was received in conjunction with the Redomiciliation of the entity organized under the laws of the U.K. and formerly named STERIS plc (""Old STERIS"") in exchange for an option to purchase 3,121 Old STERIS ordinary shares for $31.61 per share, subject to the same terms and conditions as the original Old STERIS stock option, except as otherwise required by law.",2020-12-01
0000700841,RCM TECHNOLOGIES INC,RCMT,0001158369,BALLOU ROGER H,"C/O RCM TECHNOLOGIES, INC.","2500 MCCLELLAN AVENUE, SUITE 350",PENNSAUKEN,NJ,08109,,1,0,0,0,,,"id=""F1"">Includes 15,845 restricted stock units that were reflected in reporting person's Form 4 filed on December 16, 2019.",2020-06-02
0000031462,ECOLAB INC.,ECL,0001192933,ETTINGER JEFFREY M,C/O ECOLAB INC.,1 ECOLAB PLACE,SAINT PAUL,MN,55102,,1,0,0,0,,,"id=""F1"">The option will become exercisable, on a cumulative basis, as to 25% of the option shares (excluding any fractional portion less than one share), on the last day of each of the first, second and third three-month periods following its date of grant and as to the remaining shares on the last day of the fourth three-month period following its date of grant; provided, however, that if a Change in Control of the Company (as that term is defined in the Ecolab Inc. 2001 Non-Employee Director Stock Option and Deferred Compensation Plan) will occur, then the option will become immediately exercisable in full.",
0001059556,MOODYS CORP /DE/,MCO,0001221787,FORLENZA VINCENT A,7 WORLD TRADE CENTER,250 GREENWICH STREET,NEW YORK,NY,10007,,1,0,0,0,,,"id=""F1"">RSU deferred dividend reinvestment accrual.",2020-06-10
0001059556,MOODYS CORP /DE/,MCO,0001221787,FORLENZA VINCENT A,7 WORLD TRADE CENTER,250 GREENWICH STREET,NEW YORK,NY,10007,,1,0,0,0,,,"id=""F2"">Phantom Stock Units arising out of the Reporting Person's election to defer receipt of retainer fees.",2020-06-10
0001059556,MOODYS CORP /DE/,MCO,0001221787,FORLENZA VINCENT A,7 WORLD TRADE CENTER,250 GREENWICH STREET,NEW YORK,NY,10007,,1,0,0,0,,,"id=""F3"">The security converts to common stock on a one-for-one basis.",2020-06-10
0001059556,MOODYS CORP /DE/,MCO,0001221787,FORLENZA VINCENT A,7 WORLD TRADE CENTER,250 GREENWICH STREET,NEW YORK,NY,10007,,1,0,0,0,,,"id=""F4"">These units are to be settled in cash after the Reporting Person's retirement.",2020-06-10
0001059556,MOODYS CORP /DE/,MCO,0001221787,FORLENZA VINCENT A,7 WORLD TRADE CENTER,250 GREENWICH STREET,NEW YORK,NY,10007,,1,0,0,0,,,"id=""F5"">Dividend Equivalents accrued on exempt grant of unvested RSUs, which will vest and settle with the underlying award.",2020-06-10
0000746598,BRADY CORP,BRC,0001222848,HARRIS FRANK W,872 COVENTRY STREET,,BOCA RATON,FL,33487,,1,0,0,0,,,"id=""F1"">Reporting owner acquired 2,731 unrestricted shares of Class A Common Stock as compensation for their services as a member of the Board of Directors.  Reporting owner has elected to defer the stock into his Brady Corporation Deferred Compensation account.",2020-09-30
0001227500,EQUITY BANCSHARES INC,EQBK,0001755774,Reber Brett A,"7701 E. KELLOGG DR., STE. 300",,WICHITA,KS,67207,,0,1,0,0,General Counsel,,"id=""F1"">Represents the grant of restricted stock units.  These restricted stock units vest in three equal annual installments beginning on February 7, 2021.",2020-02-07
0001227500,EQUITY BANCSHARES INC,EQBK,0001755774,Reber Brett A,"7701 E. KELLOGG DR., STE. 300",,WICHITA,KS,67207,,0,1,0,0,General Counsel,,"id=""F2"">Includes 500 shares purchased on August 14, 2019 pursuant to the Equity Bancshares, Inc. 2019 Employee Stock Purchase Plan.",2020-02-07
0000069633,"NAPCO SECURITY TECHNOLOGIES, INC",NSSC,0001286331,WILDER ANDREW,333 BAYVIEW AVE,,AMITYVILLE,NY,11701,,1,0,0,0,,,"id=""F1"">Exercisable, cumulatively, at 20% per year commencing February 12, 2020.",2020-02-12
0001333986,"Equitable Holdings, Inc.",EQH,0001705476,Malmstrom Anders,"C/O EQUITABLE HOLDINGS, INC.",1290 AVENUE OF THE AMERICAS,NEW YORK,NY,10104,,0,1,0,0,Senior EVP & CFO,,"id=""F1"">Includes restricted stock units.",2020-03-09
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F1"">Shares of common stock (""Common Stock"") of Alexion Pharmaceuticals, Inc. (the ""Issuer"") directly held by Felix J. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F2"">Common Stock directly held by Julian C. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F3"">Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in shares of Common Stock of the Issuer directly held by FBB Associates. Felix J. Baker and Julian C. Baker are the sole partners of FBB Associates. Felix J. Baker and Julian C. Baker each disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F4"">3,468 restricted stock units (each, an ""RSU'"") payable solely in Common Stock granted to Felix J. Baker on May 14, 2020 (""Grant Date"") in his capacity as a director of the Issuer pursuant to the 2017 Incentive Plan (""Stock Incentive Plan"").  The 3,468 RSUs vest on the earlier of May 14, 2021 or the annual meeting of shareholders following the Grant Date.  Additionally, on the Grant Date, 1,189 RSU's were granted to Felix J. Baker in his capacity as a director of the Issuer pursuant to the Stock Incentive Plan. The 1,189 RSUs vest in equal quarterly installments with the last installment vesting on the earlier of May 14, 2021 or the date of the annual meeting of shareholders following the Grant Date.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F5"">Felix J. Baker serves on the Issuer's Board of Directors (the ""Board"") as a representative of the Funds (as defined below). Pursuant to the policies of Baker Bros. Advisors LP (the ""Adviser""), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board, and the Funds (as defined below) are entitled to receive all the pecuniary interest in the securities issued. 667, L.P. (""667"") and Baker Brothers Life Sciences, L.P. (""Life Sciences"", and together with 667, the ""Funds"") each own an indirect proportionate pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F6"">Solely as a result of Julian C. Baker's and Felix J. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F7"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which 667 may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F8"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which Life Sciences may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F9"">This amount includes 12,763, 33,608 and 20,226 shares of Common Stock of the Issuer held directly, respectively by Julian C. Baker, Felix J. Baker and Stephen R. Biggar received from their service on the Board of Directors of Synageva Biopharma Corp. (""Synageva Board""), a company acquired by the Issuer pursuant to a merger agreement dated May 5, 2015, and its predecessor (""Predecessor Board""). Julian C. Baker, a managing member of the Adviser GP, served on the Predecessor Board. Felix J. Baker, a managing member of the Adviser GP, and Stephen R. Biggar, a full-time employee of the Adviser, served on the Synageva Board. Felix J. Baker serves on the Board.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F10"">Pursuant to the policies of the Adviser, Julian C. Baker, Felix J. Baker and Stephen R. Biggar do not have any right to any of Synageva Biopharma Corp.'s or the Issuer's securities issued as part of their service on the Board, the Synageva Board or the Predecessor Board, and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the stock options, restricted stock units or Common Stock received for service on the Board, the Synageva Board and the Predecessor Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the stock options, restricted stock units and Common Stock received from their service on the Board, the Synageva Board or the Predecessor Board (i.e. no direct pecuniary interest).",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F11"">The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the ""Adviser GP"") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F12"">The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001263508,BAKER BROS. ADVISORS LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F13"">The disclosure of the grants of RSUs reported on this form are two grants of 3,468 RSU's and  1,189 RSU's, each. The 3,468 and 1,189 RSU's are reported for each of the Funds as each has an indirect pecuniary interest.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F1"">Shares of common stock (""Common Stock"") of Alexion Pharmaceuticals, Inc. (the ""Issuer"") directly held by Felix J. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F2"">Common Stock directly held by Julian C. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F3"">Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in shares of Common Stock of the Issuer directly held by FBB Associates. Felix J. Baker and Julian C. Baker are the sole partners of FBB Associates. Felix J. Baker and Julian C. Baker each disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F4"">3,468 restricted stock units (each, an ""RSU'"") payable solely in Common Stock granted to Felix J. Baker on May 14, 2020 (""Grant Date"") in his capacity as a director of the Issuer pursuant to the 2017 Incentive Plan (""Stock Incentive Plan"").  The 3,468 RSUs vest on the earlier of May 14, 2021 or the annual meeting of shareholders following the Grant Date.  Additionally, on the Grant Date, 1,189 RSU's were granted to Felix J. Baker in his capacity as a director of the Issuer pursuant to the Stock Incentive Plan. The 1,189 RSUs vest in equal quarterly installments with the last installment vesting on the earlier of May 14, 2021 or the date of the annual meeting of shareholders following the Grant Date.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F5"">Felix J. Baker serves on the Issuer's Board of Directors (the ""Board"") as a representative of the Funds (as defined below). Pursuant to the policies of Baker Bros. Advisors LP (the ""Adviser""), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board, and the Funds (as defined below) are entitled to receive all the pecuniary interest in the securities issued. 667, L.P. (""667"") and Baker Brothers Life Sciences, L.P. (""Life Sciences"", and together with 667, the ""Funds"") each own an indirect proportionate pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F6"">Solely as a result of Julian C. Baker's and Felix J. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F7"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which 667 may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F8"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which Life Sciences may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F9"">This amount includes 12,763, 33,608 and 20,226 shares of Common Stock of the Issuer held directly, respectively by Julian C. Baker, Felix J. Baker and Stephen R. Biggar received from their service on the Board of Directors of Synageva Biopharma Corp. (""Synageva Board""), a company acquired by the Issuer pursuant to a merger agreement dated May 5, 2015, and its predecessor (""Predecessor Board""). Julian C. Baker, a managing member of the Adviser GP, served on the Predecessor Board. Felix J. Baker, a managing member of the Adviser GP, and Stephen R. Biggar, a full-time employee of the Adviser, served on the Synageva Board. Felix J. Baker serves on the Board.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F10"">Pursuant to the policies of the Adviser, Julian C. Baker, Felix J. Baker and Stephen R. Biggar do not have any right to any of Synageva Biopharma Corp.'s or the Issuer's securities issued as part of their service on the Board, the Synageva Board or the Predecessor Board, and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the stock options, restricted stock units or Common Stock received for service on the Board, the Synageva Board and the Predecessor Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the stock options, restricted stock units and Common Stock received from their service on the Board, the Synageva Board or the Predecessor Board (i.e. no direct pecuniary interest).",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F11"">The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the ""Adviser GP"") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F12"">The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001551139,"667, L.P.","860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F13"">The disclosure of the grants of RSUs reported on this form are two grants of 3,468 RSU's and  1,189 RSU's, each. The 3,468 and 1,189 RSU's are reported for each of the Funds as each has an indirect pecuniary interest.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F1"">Shares of common stock (""Common Stock"") of Alexion Pharmaceuticals, Inc. (the ""Issuer"") directly held by Felix J. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F2"">Common Stock directly held by Julian C. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F3"">Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in shares of Common Stock of the Issuer directly held by FBB Associates. Felix J. Baker and Julian C. Baker are the sole partners of FBB Associates. Felix J. Baker and Julian C. Baker each disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F4"">3,468 restricted stock units (each, an ""RSU'"") payable solely in Common Stock granted to Felix J. Baker on May 14, 2020 (""Grant Date"") in his capacity as a director of the Issuer pursuant to the 2017 Incentive Plan (""Stock Incentive Plan"").  The 3,468 RSUs vest on the earlier of May 14, 2021 or the annual meeting of shareholders following the Grant Date.  Additionally, on the Grant Date, 1,189 RSU's were granted to Felix J. Baker in his capacity as a director of the Issuer pursuant to the Stock Incentive Plan. The 1,189 RSUs vest in equal quarterly installments with the last installment vesting on the earlier of May 14, 2021 or the date of the annual meeting of shareholders following the Grant Date.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F5"">Felix J. Baker serves on the Issuer's Board of Directors (the ""Board"") as a representative of the Funds (as defined below). Pursuant to the policies of Baker Bros. Advisors LP (the ""Adviser""), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board, and the Funds (as defined below) are entitled to receive all the pecuniary interest in the securities issued. 667, L.P. (""667"") and Baker Brothers Life Sciences, L.P. (""Life Sciences"", and together with 667, the ""Funds"") each own an indirect proportionate pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F6"">Solely as a result of Julian C. Baker's and Felix J. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F7"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which 667 may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F8"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which Life Sciences may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F9"">This amount includes 12,763, 33,608 and 20,226 shares of Common Stock of the Issuer held directly, respectively by Julian C. Baker, Felix J. Baker and Stephen R. Biggar received from their service on the Board of Directors of Synageva Biopharma Corp. (""Synageva Board""), a company acquired by the Issuer pursuant to a merger agreement dated May 5, 2015, and its predecessor (""Predecessor Board""). Julian C. Baker, a managing member of the Adviser GP, served on the Predecessor Board. Felix J. Baker, a managing member of the Adviser GP, and Stephen R. Biggar, a full-time employee of the Adviser, served on the Synageva Board. Felix J. Baker serves on the Board.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F10"">Pursuant to the policies of the Adviser, Julian C. Baker, Felix J. Baker and Stephen R. Biggar do not have any right to any of Synageva Biopharma Corp.'s or the Issuer's securities issued as part of their service on the Board, the Synageva Board or the Predecessor Board, and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the stock options, restricted stock units or Common Stock received for service on the Board, the Synageva Board and the Predecessor Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the stock options, restricted stock units and Common Stock received from their service on the Board, the Synageva Board or the Predecessor Board (i.e. no direct pecuniary interest).",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F11"">The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the ""Adviser GP"") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F12"">The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001580575,Baker Bros. Advisors (GP) LLC,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F13"">The disclosure of the grants of RSUs reported on this form are two grants of 3,468 RSU's and  1,189 RSU's, each. The 3,468 and 1,189 RSU's are reported for each of the Funds as each has an indirect pecuniary interest.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F1"">Shares of common stock (""Common Stock"") of Alexion Pharmaceuticals, Inc. (the ""Issuer"") directly held by Felix J. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F2"">Common Stock directly held by Julian C. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F3"">Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in shares of Common Stock of the Issuer directly held by FBB Associates. Felix J. Baker and Julian C. Baker are the sole partners of FBB Associates. Felix J. Baker and Julian C. Baker each disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F4"">3,468 restricted stock units (each, an ""RSU'"") payable solely in Common Stock granted to Felix J. Baker on May 14, 2020 (""Grant Date"") in his capacity as a director of the Issuer pursuant to the 2017 Incentive Plan (""Stock Incentive Plan"").  The 3,468 RSUs vest on the earlier of May 14, 2021 or the annual meeting of shareholders following the Grant Date.  Additionally, on the Grant Date, 1,189 RSU's were granted to Felix J. Baker in his capacity as a director of the Issuer pursuant to the Stock Incentive Plan. The 1,189 RSUs vest in equal quarterly installments with the last installment vesting on the earlier of May 14, 2021 or the date of the annual meeting of shareholders following the Grant Date.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F5"">Felix J. Baker serves on the Issuer's Board of Directors (the ""Board"") as a representative of the Funds (as defined below). Pursuant to the policies of Baker Bros. Advisors LP (the ""Adviser""), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board, and the Funds (as defined below) are entitled to receive all the pecuniary interest in the securities issued. 667, L.P. (""667"") and Baker Brothers Life Sciences, L.P. (""Life Sciences"", and together with 667, the ""Funds"") each own an indirect proportionate pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F6"">Solely as a result of Julian C. Baker's and Felix J. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F7"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which 667 may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F8"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which Life Sciences may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F9"">This amount includes 12,763, 33,608 and 20,226 shares of Common Stock of the Issuer held directly, respectively by Julian C. Baker, Felix J. Baker and Stephen R. Biggar received from their service on the Board of Directors of Synageva Biopharma Corp. (""Synageva Board""), a company acquired by the Issuer pursuant to a merger agreement dated May 5, 2015, and its predecessor (""Predecessor Board""). Julian C. Baker, a managing member of the Adviser GP, served on the Predecessor Board. Felix J. Baker, a managing member of the Adviser GP, and Stephen R. Biggar, a full-time employee of the Adviser, served on the Synageva Board. Felix J. Baker serves on the Board.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F10"">Pursuant to the policies of the Adviser, Julian C. Baker, Felix J. Baker and Stephen R. Biggar do not have any right to any of Synageva Biopharma Corp.'s or the Issuer's securities issued as part of their service on the Board, the Synageva Board or the Predecessor Board, and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the stock options, restricted stock units or Common Stock received for service on the Board, the Synageva Board and the Predecessor Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the stock options, restricted stock units and Common Stock received from their service on the Board, the Synageva Board or the Predecessor Board (i.e. no direct pecuniary interest).",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F11"">The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the ""Adviser GP"") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F12"">The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001363364,Baker Brothers Life Sciences LP,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F13"">The disclosure of the grants of RSUs reported on this form are two grants of 3,468 RSU's and  1,189 RSU's, each. The 3,468 and 1,189 RSU's are reported for each of the Funds as each has an indirect pecuniary interest.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F1"">Shares of common stock (""Common Stock"") of Alexion Pharmaceuticals, Inc. (the ""Issuer"") directly held by Felix J. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F2"">Common Stock directly held by Julian C. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F3"">Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in shares of Common Stock of the Issuer directly held by FBB Associates. Felix J. Baker and Julian C. Baker are the sole partners of FBB Associates. Felix J. Baker and Julian C. Baker each disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F4"">3,468 restricted stock units (each, an ""RSU'"") payable solely in Common Stock granted to Felix J. Baker on May 14, 2020 (""Grant Date"") in his capacity as a director of the Issuer pursuant to the 2017 Incentive Plan (""Stock Incentive Plan"").  The 3,468 RSUs vest on the earlier of May 14, 2021 or the annual meeting of shareholders following the Grant Date.  Additionally, on the Grant Date, 1,189 RSU's were granted to Felix J. Baker in his capacity as a director of the Issuer pursuant to the Stock Incentive Plan. The 1,189 RSUs vest in equal quarterly installments with the last installment vesting on the earlier of May 14, 2021 or the date of the annual meeting of shareholders following the Grant Date.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F5"">Felix J. Baker serves on the Issuer's Board of Directors (the ""Board"") as a representative of the Funds (as defined below). Pursuant to the policies of Baker Bros. Advisors LP (the ""Adviser""), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board, and the Funds (as defined below) are entitled to receive all the pecuniary interest in the securities issued. 667, L.P. (""667"") and Baker Brothers Life Sciences, L.P. (""Life Sciences"", and together with 667, the ""Funds"") each own an indirect proportionate pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F6"">Solely as a result of Julian C. Baker's and Felix J. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F7"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which 667 may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F8"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which Life Sciences may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F9"">This amount includes 12,763, 33,608 and 20,226 shares of Common Stock of the Issuer held directly, respectively by Julian C. Baker, Felix J. Baker and Stephen R. Biggar received from their service on the Board of Directors of Synageva Biopharma Corp. (""Synageva Board""), a company acquired by the Issuer pursuant to a merger agreement dated May 5, 2015, and its predecessor (""Predecessor Board""). Julian C. Baker, a managing member of the Adviser GP, served on the Predecessor Board. Felix J. Baker, a managing member of the Adviser GP, and Stephen R. Biggar, a full-time employee of the Adviser, served on the Synageva Board. Felix J. Baker serves on the Board.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F10"">Pursuant to the policies of the Adviser, Julian C. Baker, Felix J. Baker and Stephen R. Biggar do not have any right to any of Synageva Biopharma Corp.'s or the Issuer's securities issued as part of their service on the Board, the Synageva Board or the Predecessor Board, and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the stock options, restricted stock units or Common Stock received for service on the Board, the Synageva Board and the Predecessor Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the stock options, restricted stock units and Common Stock received from their service on the Board, the Synageva Board or the Predecessor Board (i.e. no direct pecuniary interest).",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F11"">The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the ""Adviser GP"") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F12"">The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087940,BAKER FELIX,860 WASHINGTON STREET,3RD FLOOR,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F13"">The disclosure of the grants of RSUs reported on this form are two grants of 3,468 RSU's and  1,189 RSU's, each. The 3,468 and 1,189 RSU's are reported for each of the Funds as each has an indirect pecuniary interest.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F1"">Shares of common stock (""Common Stock"") of Alexion Pharmaceuticals, Inc. (the ""Issuer"") directly held by Felix J. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F2"">Common Stock directly held by Julian C. Baker.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F3"">Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in shares of Common Stock of the Issuer directly held by FBB Associates. Felix J. Baker and Julian C. Baker are the sole partners of FBB Associates. Felix J. Baker and Julian C. Baker each disclaim beneficial ownership of the securities held directly by FBB Associates except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that Felix J. Baker or Julian C. Baker is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F4"">3,468 restricted stock units (each, an ""RSU'"") payable solely in Common Stock granted to Felix J. Baker on May 14, 2020 (""Grant Date"") in his capacity as a director of the Issuer pursuant to the 2017 Incentive Plan (""Stock Incentive Plan"").  The 3,468 RSUs vest on the earlier of May 14, 2021 or the annual meeting of shareholders following the Grant Date.  Additionally, on the Grant Date, 1,189 RSU's were granted to Felix J. Baker in his capacity as a director of the Issuer pursuant to the Stock Incentive Plan. The 1,189 RSUs vest in equal quarterly installments with the last installment vesting on the earlier of May 14, 2021 or the date of the annual meeting of shareholders following the Grant Date.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F5"">Felix J. Baker serves on the Issuer's Board of Directors (the ""Board"") as a representative of the Funds (as defined below). Pursuant to the policies of Baker Bros. Advisors LP (the ""Adviser""), Felix J. Baker does not have any right to any of the Issuer's securities issued as part of his service on the Board, and the Funds (as defined below) are entitled to receive all the pecuniary interest in the securities issued. 667, L.P. (""667"") and Baker Brothers Life Sciences, L.P. (""Life Sciences"", and together with 667, the ""Funds"") each own an indirect proportionate pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F6"">Solely as a result of Julian C. Baker's and Felix J. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the RSUs.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F7"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which 667 may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F8"">After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital L.P. and (ii) Life Sciences, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in Common Stock reported in column 5 of Table I directly held by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences. This amount includes beneficial ownership of 13,118 shares of Common Stock issued, 8,461 of which were received previously, pursuant to the Stock Incentive Plan in lieu of director retainer fees and an annual grant, of which Life Sciences may be deemed to own a portion.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F9"">This amount includes 12,763, 33,608 and 20,226 shares of Common Stock of the Issuer held directly, respectively by Julian C. Baker, Felix J. Baker and Stephen R. Biggar received from their service on the Board of Directors of Synageva Biopharma Corp. (""Synageva Board""), a company acquired by the Issuer pursuant to a merger agreement dated May 5, 2015, and its predecessor (""Predecessor Board""). Julian C. Baker, a managing member of the Adviser GP, served on the Predecessor Board. Felix J. Baker, a managing member of the Adviser GP, and Stephen R. Biggar, a full-time employee of the Adviser, served on the Synageva Board. Felix J. Baker serves on the Board.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F10"">Pursuant to the policies of the Adviser, Julian C. Baker, Felix J. Baker and Stephen R. Biggar do not have any right to any of Synageva Biopharma Corp.'s or the Issuer's securities issued as part of their service on the Board, the Synageva Board or the Predecessor Board, and the Funds are entitled to receive all the pecuniary interest in the securities issued. The Funds each own an indirect proportionate pecuniary interest in the stock options, restricted stock units or Common Stock received for service on the Board, the Synageva Board and the Predecessor Board. Solely as a result of Felix J. Baker's and Julian C. Baker's ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the stock options, restricted stock units and Common Stock received from their service on the Board, the Synageva Board or the Predecessor Board (i.e. no direct pecuniary interest).",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F11"">The Adviser serves as the Investment Adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. Baker Bros. Advisors (GP) LLC (the ""Adviser GP"") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F12"">The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds. Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.",
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001087939,BAKER JULIAN,"860 WASHINGTON STREET, 3RD FLOOR",,NEW YORK,NY,10014,,1,0,0,0,,,"id=""F13"">The disclosure of the grants of RSUs reported on this form are two grants of 3,468 RSU's and  1,189 RSU's, each. The 3,468 and 1,189 RSU's are reported for each of the Funds as each has an indirect pecuniary interest.",
0001370450,"Willdan Group, Inc.",WLDN,0001733724,WHITELAW PAUL MILTON,2401 E. KATELLA AVE,SUITE 300,ANAHEIM,CA,92806,,0,1,0,0,"SVP, Business Development",,"id=""F1"">Represents shares of the Issuer's Common Stock withheld for tax withholding purposes in connection with the vesting of restricted stock on October 31, 2019, which restricted stock was granted on October 21, 2017.",2019-10-31
0001370450,"Willdan Group, Inc.",WLDN,0001733724,WHITELAW PAUL MILTON,2401 E. KATELLA AVE,SUITE 300,ANAHEIM,CA,92806,,0,1,0,0,"SVP, Business Development",,"id=""F2"">Includes (i) 444 shares of restricted stock that vest on March 8, 2020, (ii) 444 shares of restricted stock that vest on October 31, 2020 and (iii) an aggregate of 1,164 shares of Common Stock purchased under the Amended and Restated Willdan Group, Inc. 2006 Employee Stock Purchase Plan, including 225 shares on December 31, 2016, 229 shares on June 30, 2017, 225 shares on December 31, 2017, 355 shares on June 30, 2018 and 130 shares on December 31, 2018.",2019-10-31
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F1"">Each restricted stock unit is convertible into a share of common stock on a 1-for-1 basis. The restricted stock units vested in common stock on February 22, 2020.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F2"">Shares withheld by the Company to satisfy tax withholding requirements.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F3"">Each restricted stock unit is convertible into a share of common stock on a 1-for-1 basis.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F4"">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock as follows: one-third of these restricted stock units vested on May 12, 2018, one-third of these restricted stock units vested on May 12, 2019 and the remaining one-third of these restricted stock units vest on May 12, 2020, assuming continued employment through the applicable vesting date.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F5"">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock as follows: one-third of these restricted stock units vested on March 2, 2019, one-third of these restricted stock units vest on March 2, 2020 and the remaining one-third of these restricted stock units vest on March 2, 2021, assuming continued employment through the applicable vesting date.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F6"">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock as follows: one-third of these restricted stock units vested on February 22, 2020, one-third of these restricted stock units vest on February 22, 2021 and the remaining one-third of these restricted stock units vest on February 22, 2022, assuming continued employment through the applicable vesting date.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F7"">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock on May 12, 2020, assuming continued employment through the applicable vesting date.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F8"">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock on March 2, 2021, assuming continued employment through the applicable vesting date.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F9"">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock on February 22, 2022, assuming continued employment through the applicable vesting date.",2020-02-22
0001395942,"KAR Auction Services, Inc.",KAR,0001597236,Fisher Thomas J,"C/O: KAR AUCTION SERVICES, INC.",11299 NORTH ILLINOIS STREET,CARMEL,IN,46032,,0,1,0,0,"EVP, Chief Information Officer",,"id=""F10"">These restricted stock units remain subject to a time-vesting requirement and are scheduled to vest and settle in common stock as follows: one-third of these restricted stock units vest on February 21, 2021, one-third of these restricted stock units vest on February 21, 2022 and the remaining one-third of these restricted stock units vest on February 21, 2023, assuming continued employment through the applicable vesting date.",2020-02-22
0001403161,VISA INC.,V,0001209832,PRABHU VASANT M,C/O VISA INC.,P.O. BOX 8999,SAN FRANCISCO,CA,94128-8999,,,1,,,VICE CHAIR & CFO,,"id=""F1"">The price reported in column 4 is a weighted average price. These shares were disposed of in multiple transactions at prices ranging from $197.0000-$197.3500, inclusive. The reporting person undertakes to provide to Visa Inc., any security holder of Visa Inc., or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares disposed of at each separate price within the ranges set forth in this Form 4.",2020-06-02
0000805928,"Axogen, Inc.",AXGN,0001403679,Rudelius Robert James,13631 PROGRESS BOULEVARD,SUITE 400,ALACHUA,FL,32615,,1,0,0,0,,,"id=""F1"">Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2021, one year from the anniversary of the grant date. Two-thirds of the annual equity grant value is in the form of non-qualified stock options and one-third of the annual equity grant value is in the form of restricted stock units.",2020-06-01
0000805928,"Axogen, Inc.",AXGN,0001403679,Rudelius Robert James,13631 PROGRESS BOULEVARD,SUITE 400,ALACHUA,FL,32615,,1,0,0,0,,,"id=""F2"">Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.",2020-06-01
0001412408,"Phreesia, Inc.",PHR,0001776863,VanDuyn Amy Beth,"C/O PHREESIA, INC.","432 PARK AVENUE SOUTH, 12TH FLOOR",NEW YORK,NY,10016,,0,1,0,0,"SVP, Human Resources",,"id=""F1"">The shares reported in this transaction represent Restricted Stock Units (""RSUs"") issued under the Phreesia, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest as follows: 10% of the RSUs shall vest on January 15, 2021, 20% of the RSUs shall vest on January 15, 2022, 30% of the RSUs shall vest on January 15, 2023 and 40% of the RSUs shall vest on January 15, 2024, subject to the Reporting Person's continued service to the Issuer through each vesting date.",2020-01-15
0001412408,"Phreesia, Inc.",PHR,0001776863,VanDuyn Amy Beth,"C/O PHREESIA, INC.","432 PARK AVENUE SOUTH, 12TH FLOOR",NEW YORK,NY,10016,,0,1,0,0,"SVP, Human Resources",,"id=""F2"">These shares are subject to a Lock-Up Agreement until January 26, 2020.",2020-01-15
0001412408,"Phreesia, Inc.",PHR,0001776863,VanDuyn Amy Beth,"C/O PHREESIA, INC.","432 PARK AVENUE SOUTH, 12TH FLOOR",NEW YORK,NY,10016,,0,1,0,0,"SVP, Human Resources",,"id=""F3"">A portion of these shares represent RSUs.",2020-01-15
0001764925,"Slack Technologies, Inc.",WORK,0001419457,Accel X LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F1"">Each share of Class B Common Stock is convertible without payment or consideration into one share of Class A Common Stock at the option of the holder and has no expiration date.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001419457,Accel X LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F2"">These shares are held by Accel X L.P.  Accel X Associates L.L.C. (""Accel X GP"") is the general partner of each of Accel X L.P. and Accel X Strategic Partners L.P. (together, the ""Accel X Entities""). Accel X GP has sole voting and dispositive power with regard to the shares held by the Accel X Entities. Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001419457,Accel X LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F3"">On January 13, 2020, Accel X L.P. distributed, for no consideration, 4,931,850 shares of Class A common stock of the Issuer (the ""Accel X Shares"") to its limited partners and to Accel X GP, the general partner of Accel X L.P., representing each such partner's pro rata interest in such Accel X Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Shares it received in the distribution by Accel X L.P. to its members, representing each such member's pro rata interest in such Accel X Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001419457,Accel X LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F4"">These shares are held by Accel X Strategic Partners L.P.  Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001419457,Accel X LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F5"">On January 13, 2020, Accel X Strategic Partners L.P. distributed, for no consideration, 370,150 shares of Class A common stock of the Issuer (the ""Accel X Strategic Shares"") to its limited partners and to Accel X GP, the general partner of Accel X Strategic Partners L.P., representing each such partner's pro rata interest in such Accel X Strategic Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Strategic Shares it received in the distribution by the Fund to its members, representing each such member's pro rata interest in such Accel X Strategic Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001419457,Accel X LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F6"">These shares are held by Accel Investors 2009 L.L.C.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001419457,Accel X LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F7"">On January 13, 2020, Accel Investors 2009 L.L.C. distributed, for no consideration, 198,000 shares of Class A common stock of the Issuer (the ""Accel 2009 Shares"") to its members, representing each such member's pro rata interest in such Accel 2009 Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001430231,ACCEL X STRATEGIC PARTNERS LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F1"">Each share of Class B Common Stock is convertible without payment or consideration into one share of Class A Common Stock at the option of the holder and has no expiration date.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001430231,ACCEL X STRATEGIC PARTNERS LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F2"">These shares are held by Accel X L.P.  Accel X Associates L.L.C. (""Accel X GP"") is the general partner of each of Accel X L.P. and Accel X Strategic Partners L.P. (together, the ""Accel X Entities""). Accel X GP has sole voting and dispositive power with regard to the shares held by the Accel X Entities. Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001430231,ACCEL X STRATEGIC PARTNERS LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F3"">On January 13, 2020, Accel X L.P. distributed, for no consideration, 4,931,850 shares of Class A common stock of the Issuer (the ""Accel X Shares"") to its limited partners and to Accel X GP, the general partner of Accel X L.P., representing each such partner's pro rata interest in such Accel X Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Shares it received in the distribution by Accel X L.P. to its members, representing each such member's pro rata interest in such Accel X Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001430231,ACCEL X STRATEGIC PARTNERS LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F4"">These shares are held by Accel X Strategic Partners L.P.  Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001430231,ACCEL X STRATEGIC PARTNERS LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F5"">On January 13, 2020, Accel X Strategic Partners L.P. distributed, for no consideration, 370,150 shares of Class A common stock of the Issuer (the ""Accel X Strategic Shares"") to its limited partners and to Accel X GP, the general partner of Accel X Strategic Partners L.P., representing each such partner's pro rata interest in such Accel X Strategic Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Strategic Shares it received in the distribution by the Fund to its members, representing each such member's pro rata interest in such Accel X Strategic Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001430231,ACCEL X STRATEGIC PARTNERS LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F6"">These shares are held by Accel Investors 2009 L.L.C.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001430231,ACCEL X STRATEGIC PARTNERS LP,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F7"">On January 13, 2020, Accel Investors 2009 L.L.C. distributed, for no consideration, 198,000 shares of Class A common stock of the Issuer (the ""Accel 2009 Shares"") to its members, representing each such member's pro rata interest in such Accel 2009 Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494996,Accel X Associates L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F1"">Each share of Class B Common Stock is convertible without payment or consideration into one share of Class A Common Stock at the option of the holder and has no expiration date.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494996,Accel X Associates L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F2"">These shares are held by Accel X L.P.  Accel X Associates L.L.C. (""Accel X GP"") is the general partner of each of Accel X L.P. and Accel X Strategic Partners L.P. (together, the ""Accel X Entities""). Accel X GP has sole voting and dispositive power with regard to the shares held by the Accel X Entities. Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494996,Accel X Associates L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F3"">On January 13, 2020, Accel X L.P. distributed, for no consideration, 4,931,850 shares of Class A common stock of the Issuer (the ""Accel X Shares"") to its limited partners and to Accel X GP, the general partner of Accel X L.P., representing each such partner's pro rata interest in such Accel X Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Shares it received in the distribution by Accel X L.P. to its members, representing each such member's pro rata interest in such Accel X Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494996,Accel X Associates L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F4"">These shares are held by Accel X Strategic Partners L.P.  Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494996,Accel X Associates L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F5"">On January 13, 2020, Accel X Strategic Partners L.P. distributed, for no consideration, 370,150 shares of Class A common stock of the Issuer (the ""Accel X Strategic Shares"") to its limited partners and to Accel X GP, the general partner of Accel X Strategic Partners L.P., representing each such partner's pro rata interest in such Accel X Strategic Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Strategic Shares it received in the distribution by the Fund to its members, representing each such member's pro rata interest in such Accel X Strategic Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494996,Accel X Associates L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F6"">These shares are held by Accel Investors 2009 L.L.C.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494996,Accel X Associates L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F7"">On January 13, 2020, Accel Investors 2009 L.L.C. distributed, for no consideration, 198,000 shares of Class A common stock of the Issuer (the ""Accel 2009 Shares"") to its members, representing each such member's pro rata interest in such Accel 2009 Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494979,Accel Investors 2009 L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F1"">Each share of Class B Common Stock is convertible without payment or consideration into one share of Class A Common Stock at the option of the holder and has no expiration date.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494979,Accel Investors 2009 L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F2"">These shares are held by Accel X L.P.  Accel X Associates L.L.C. (""Accel X GP"") is the general partner of each of Accel X L.P. and Accel X Strategic Partners L.P. (together, the ""Accel X Entities""). Accel X GP has sole voting and dispositive power with regard to the shares held by the Accel X Entities. Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494979,Accel Investors 2009 L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F3"">On January 13, 2020, Accel X L.P. distributed, for no consideration, 4,931,850 shares of Class A common stock of the Issuer (the ""Accel X Shares"") to its limited partners and to Accel X GP, the general partner of Accel X L.P., representing each such partner's pro rata interest in such Accel X Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Shares it received in the distribution by Accel X L.P. to its members, representing each such member's pro rata interest in such Accel X Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494979,Accel Investors 2009 L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F4"">These shares are held by Accel X Strategic Partners L.P.  Accel X GP disclaims Section 16 beneficial ownership over the securities reported herein except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that such reporting person is the beneficial owner of such securities for Section 16 or any other purpose.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494979,Accel Investors 2009 L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F5"">On January 13, 2020, Accel X Strategic Partners L.P. distributed, for no consideration, 370,150 shares of Class A common stock of the Issuer (the ""Accel X Strategic Shares"") to its limited partners and to Accel X GP, the general partner of Accel X Strategic Partners L.P., representing each such partner's pro rata interest in such Accel X Strategic Shares. On the same date, Accel X GP distributed, for no consideration, the Accel X Strategic Shares it received in the distribution by the Fund to its members, representing each such member's pro rata interest in such Accel X Strategic Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494979,Accel Investors 2009 L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F6"">These shares are held by Accel Investors 2009 L.L.C.",2020-01-13
0001764925,"Slack Technologies, Inc.",WORK,0001494979,Accel Investors 2009 L.L.C.,500 UNIVERSITY AVENUE,,PALO ALTO,CA,94301,,0,0,1,0,,,"id=""F7"">On January 13, 2020, Accel Investors 2009 L.L.C. distributed, for no consideration, 198,000 shares of Class A common stock of the Issuer (the ""Accel 2009 Shares"") to its members, representing each such member's pro rata interest in such Accel 2009 Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.",2020-01-13
0001393726,TIPTREE INC.,TIPT,0001447887,Bell Sandra,C/O TIPTREE INC.,"299 PARK AVENUE, 13TH FL.",NEW YORK,NY,10171,,0,1,0,0,Chief Financial Officer,,"id=""F1"">The Reporting Person was granted restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, pursuant to the Issuer's Equity Plan.  The restricted stock units will vest annually in three equal installments on each of February 15, 2021, 2022 and 2023 upon continuous employment from the grant date until such date, subject to certain terms contained in the Reporting Person's award agreement.",2020-02-20
0001357615,"KBR, INC.",KBR,0001448238,Carney Raymond L. Jr.,601 JEFFERSON STREET,,HOUSTON,TX,77002,,0,1,0,0,VP & Chief Accounting Officer,,"id=""F1"">Represents shares withheld to pay withholding taxes due upon vestings.",2020-02-28
0001467858,General Motors Co,GM,0001292153,Hatto Christopher,300 RENAISSANCE CENTER,M/C: 482-C23-A68,DETROIT,MI,48265,,0,1,0,0,Vice President & CAO,,"id=""F1"">The Restricted Stock Units (""RSUs"") reported in this item were awarded on May 7, 2020, pursuant to the Company's 2017 Long-Term Incentive Plan. The RSUs will vest on April 1, 2021.",2020-05-07
0001467858,General Motors Co,GM,0001292153,Hatto Christopher,300 RENAISSANCE CENTER,M/C: 482-C23-A68,DETROIT,MI,48265,,0,1,0,0,Vice President & CAO,,"id=""F2"">Each RSU will be settled for one share of the Company's Common Stock.",2020-05-07
0001157647,"Western New England Bancorp, Inc.",WNEB,0001474838,Gorman Louis O III,"C/O WESTERN NEW ENGLAND BANCORP, INC.",141 ELM STREET,WESTFIELD,MA,01085,,0,1,0,0,SVP & Chief Credit Officer,,"id=""F1"">These shares were issued to the reporting person pursuant to the Western New England Bancorp, Inc. 2017 Long-Term Incentive Plan, which provided for the award of shares of common stock of the Company based on the Company's performance over a designated three-year period.",2020-02-27
0001157647,"Western New England Bancorp, Inc.",WNEB,0001474838,Gorman Louis O III,"C/O WESTERN NEW ENGLAND BANCORP, INC.",141 ELM STREET,WESTFIELD,MA,01085,,0,1,0,0,SVP & Chief Credit Officer,,"id=""F2"">Reflects shares of common stock surrendered to the Issuer to satisfy tax withholding obligations in connection with the award of common stock described in footnote 1.",2020-02-27
0001478320,Adaptive Biotechnologies Corp,ADPT,0001780790,HILL NANCY LOUISE,C/O ADAPTIVE BIOTECHNOLOGIES CORP.,SUITE 200,SEATTLE,WA,98102,,0,1,0,0,"SVP, Operations",,"id=""F1"">The options vest with respect to 1/4 of such shares on February 13, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.",2020-02-13
0001787384,"FFBW, Inc. /MD/",FFBW,0001480691,Schaefer Edward H,1360 SOUTH MOORLAND ROAD,,BROOKFIELD,WI,53005,,1,1,0,0,President and CEO,,"id=""F1"">Includes shares of restricted stock which vest at a rate of 20% per year commencing on December 19, 2019.",2020-04-28
0001787384,"FFBW, Inc. /MD/",FFBW,0001480691,Schaefer Edward H,1360 SOUTH MOORLAND ROAD,,BROOKFIELD,WI,53005,,1,1,0,0,President and CEO,,"id=""F2"">Stock options vest at a rate of 20% per year commencing on December 19, 2019.",2020-04-28
0001672013,Acushnet Holdings Corp.,GOLF,0001484631,Gibbons Brendan M.,C/O ACUSHNET HOLDINGS CORP.,333 BRIDGE STREET,FAIRHAVEN,MA,02179,,,1,,,See Remarks,,"id=""F1"">Represents dividend equivalent rights in connection with the Issuer's quarterly dividend and accrued to the Reporting Person on restricted stock units deferred under the Issuer's deferred compensation plan.",2020-09-18
0001487371,"GenMark Diagnostics, Inc.",GNMK,0001632002,Kagnoff Michael,5964 LA PLACE COURT,,CARLSBAD,CA,92008,,1,0,0,0,,,"id=""F1"">The price reported is the weighted average price per share.  Shares were purchased in multiple transactions at prices ranging from $4.60 to $4.62 per share.  The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each price.",2020-03-04
0000009389,BALL Corp,BLL,0001491060,Knobel Jeff A,10 LONGS PEAK DRIVE,,BROOMFIELD,CO,80005,,false,true,false,false,Vice President & Treasurer,,"id=""F1"">Common stock acquired upon the lapse of Table II Restricted Stock Units based on the applicable Ball Corporation Stock and Cash Incentive Plan performance factor and in accordance with the provisions of said Plan.",2020-09-15
0000009389,BALL Corp,BLL,0001491060,Knobel Jeff A,10 LONGS PEAK DRIVE,,BROOMFIELD,CO,80005,,false,true,false,false,Vice President & Treasurer,,"id=""F2"">Shares withheld for the payment of the tax obligation on the lapse of restrictions on Table II Performance Contingent Restricted Stock.",2020-09-15
0000009389,BALL Corp,BLL,0001491060,Knobel Jeff A,10 LONGS PEAK DRIVE,,BROOMFIELD,CO,80005,,false,true,false,false,Vice President & Treasurer,,"id=""F3"">Total number of 401(k) Plan shares acquired through periodic dividend reinvestment, participant's contributions and employer matching contributions.",2020-09-15
0000009389,BALL Corp,BLL,0001491060,Knobel Jeff A,10 LONGS PEAK DRIVE,,BROOMFIELD,CO,80005,,false,true,false,false,Vice President & Treasurer,,"id=""F4"">Each restricted stock unit represents a contingent right to receive one share of Ball Corporation Common Stock.",2020-09-15
0000009389,BALL Corp,BLL,0001491060,Knobel Jeff A,10 LONGS PEAK DRIVE,,BROOMFIELD,CO,80005,,false,true,false,false,Vice President & Treasurer,,"id=""F5"">Lapse of restricted stock units.",2020-09-15
0001490892,CoreSite Realty Corp,COR,0001501294,"Carlyle Realty III, GP, L.L.C.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501294,"Carlyle Realty III, GP, L.L.C.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501297,"Carlyle Realty III, L.P.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501297,"Carlyle Realty III, L.P.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501694,"CoreSite CRP III Holdings, LLC","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501694,"CoreSite CRP III Holdings, LLC","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501300,"CRP III AIV GP, L.L.C.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501300,"CRP III AIV GP, L.L.C.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501301,"CRP III AIV GP, L.P.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501301,"CRP III AIV GP, L.P.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501512,"CRQP III AIV, L.P.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501512,"CRQP III AIV, L.P.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001641308,"CoreSite CRP III Holdings (VCOC), LLC","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001641308,"CoreSite CRP III Holdings (VCOC), LLC","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501299,"Carlyle Realty IV GP, L.L.C.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501299,"Carlyle Realty IV GP, L.L.C.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501302,"Carlyle Realty IV, L.P.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501302,"Carlyle Realty IV, L.P.","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501695,"CoreSite CRP IV Holdings, LLC","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F1"">The operating partnership units are redeemable at any time for cash or, at the election of the Issuer, exchangeable for shares of common stock on a one-for-one basis, and have no expiration date.",2020-08-05
0001490892,CoreSite Realty Corp,COR,0001501695,"CoreSite CRP IV Holdings, LLC","C/O THE CARLYLE GROUP, 1001","PENNSYLVANIA AVE., N.W. SUITE 220 SOUTH",WASHINGTON,DC,20004-2505,,0,0,1,0,,,"id=""F2"">Carlyle Realty III GP, L.L.C. is the general partner of Carlyle Realty III, L.P., which is the manager of CoreSite CRP III Holdings, LLC. CRP III AIV GP, L.L.C. is the general partner of CRP III AIV GP, L.P., which is the general partner of CRQP III AIV, L.P., which is the sole member of CoreSite CRP III Holdings (VCOC), LLC. Carlyle Realty IV GP, L.L.C. is the general partner of Carlyle Realty IV, L.P., which is the manager of CoreSite CRP IV Holdings, LLC. CRP IV AIV GP, L.L.C. is the general partner of CRP IV AIV GP, L.P., which is the general partner of each of CRP IV-A AIV, L.P. and CRQP IV AIV, L.P., which are the managing members of CoreSite CRP IV Holdings (VCOC I), LLC and CoreSite CRP IV Holdings (VCOC II), LLC, respectively.",2020-08-05
0001505512,Regulus Therapeutics Inc.,RGLS,0001706444,"Growth Equity Opportunities V, LLC",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F1"">Acquired from the Issuer pursuant to a Securities Purchase Agreement dated December 1, 2020 with a closing date of December 4, 2020.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001706444,"Growth Equity Opportunities V, LLC",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F2"">The securities are directly held by Growth Equity Opportunities Fund V, LLC (""GEO V"") and indirectly held by New Enterprise Associates 16, L.P. (""NEA 16""), the sole member of GEO V, NEA Partners 16, L.P. (""NEA Partners""), the
sole general partner of NEA 16, NEA 16 GP, LLC (""NEA 16 GP""), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA 16, NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the ""Indirect Reporting Persons""). The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, Scott D. Sandell, Peter W. Sonsini and Paul
Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities of the Issuer held by GEO V in
which the Indirect Reporting Persons have no pecuinary interest.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001706444,"Growth Equity Opportunities V, LLC",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F3"">Each share of Class A-3 Convertible Preferred Stock, par value $0.001 per share (""Class A-3 Preferred Stock""), of the Issuer is convertible at any time into a number of shares of common stock, par value $0.001 (""Common Stock""), of
the Issuer at a rate of 10 shares of Common Stock for each share of Class A-3 Preferred Stock, for no additional consideration, in each case subject to customary adjustments under the certificate of designations for the Class A-3 Preferred Stock (the ""Certificate of Designations""). Unless converted pursuant to its terms, the Class A-3 Preferred Stock does not expire. The Certificate of Designations prohibits conversion to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001694560,"New Enterprise Associates 16, L.P.",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F1"">Acquired from the Issuer pursuant to a Securities Purchase Agreement dated December 1, 2020 with a closing date of December 4, 2020.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001694560,"New Enterprise Associates 16, L.P.",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F2"">The securities are directly held by Growth Equity Opportunities Fund V, LLC (""GEO V"") and indirectly held by New Enterprise Associates 16, L.P. (""NEA 16""), the sole member of GEO V, NEA Partners 16, L.P. (""NEA Partners""), the
sole general partner of NEA 16, NEA 16 GP, LLC (""NEA 16 GP""), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA 16, NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the ""Indirect Reporting Persons""). The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, Scott D. Sandell, Peter W. Sonsini and Paul
Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities of the Issuer held by GEO V in
which the Indirect Reporting Persons have no pecuinary interest.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001694560,"New Enterprise Associates 16, L.P.",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F3"">Each share of Class A-3 Convertible Preferred Stock, par value $0.001 per share (""Class A-3 Preferred Stock""), of the Issuer is convertible at any time into a number of shares of common stock, par value $0.001 (""Common Stock""), of
the Issuer at a rate of 10 shares of Common Stock for each share of Class A-3 Preferred Stock, for no additional consideration, in each case subject to customary adjustments under the certificate of designations for the Class A-3 Preferred Stock (the ""Certificate of Designations""). Unless converted pursuant to its terms, the Class A-3 Preferred Stock does not expire. The Certificate of Designations prohibits conversion to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001712881,"NEA Partners 16, L.P.",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F1"">Acquired from the Issuer pursuant to a Securities Purchase Agreement dated December 1, 2020 with a closing date of December 4, 2020.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001712881,"NEA Partners 16, L.P.",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F2"">The securities are directly held by Growth Equity Opportunities Fund V, LLC (""GEO V"") and indirectly held by New Enterprise Associates 16, L.P. (""NEA 16""), the sole member of GEO V, NEA Partners 16, L.P. (""NEA Partners""), the
sole general partner of NEA 16, NEA 16 GP, LLC (""NEA 16 GP""), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA 16, NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the ""Indirect Reporting Persons""). The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, Scott D. Sandell, Peter W. Sonsini and Paul
Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities of the Issuer held by GEO V in
which the Indirect Reporting Persons have no pecuinary interest.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001712881,"NEA Partners 16, L.P.",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F3"">Each share of Class A-3 Convertible Preferred Stock, par value $0.001 per share (""Class A-3 Preferred Stock""), of the Issuer is convertible at any time into a number of shares of common stock, par value $0.001 (""Common Stock""), of
the Issuer at a rate of 10 shares of Common Stock for each share of Class A-3 Preferred Stock, for no additional consideration, in each case subject to customary adjustments under the certificate of designations for the Class A-3 Preferred Stock (the ""Certificate of Designations""). Unless converted pursuant to its terms, the Class A-3 Preferred Stock does not expire. The Certificate of Designations prohibits conversion to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001712882,"NEA 16 GP, LLC",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F1"">Acquired from the Issuer pursuant to a Securities Purchase Agreement dated December 1, 2020 with a closing date of December 4, 2020.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001712882,"NEA 16 GP, LLC",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F2"">The securities are directly held by Growth Equity Opportunities Fund V, LLC (""GEO V"") and indirectly held by New Enterprise Associates 16, L.P. (""NEA 16""), the sole member of GEO V, NEA Partners 16, L.P. (""NEA Partners""), the
sole general partner of NEA 16, NEA 16 GP, LLC (""NEA 16 GP""), the sole general partner of NEA Partners 16, and the individual managers of NEA 16 GP (NEA 16, NEA Partners 16, NEA 16 GP and the individual managers of NEA 16 GP, together, the ""Indirect Reporting Persons""). The individual managers of NEA 16 GP are Forest Baskett, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad Makhzoumi, Josh Makower, Scott D. Sandell, Peter W. Sonsini and Paul
Walker. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities of the Issuer held by GEO V in
which the Indirect Reporting Persons have no pecuinary interest.",2020-12-04
0001505512,Regulus Therapeutics Inc.,RGLS,0001712882,"NEA 16 GP, LLC",1954 GREENSPRING DRIVE,SUITE 600,TIMONIUM,MD,21093,,0,0,1,0,,,"id=""F3"">Each share of Class A-3 Convertible Preferred Stock, par value $0.001 per share (""Class A-3 Preferred Stock""), of the Issuer is convertible at any time into a number of shares of common stock, par value $0.001 (""Common Stock""), of
the Issuer at a rate of 10 shares of Common Stock for each share of Class A-3 Preferred Stock, for no additional consideration, in each case subject to customary adjustments under the certificate of designations for the Class A-3 Preferred Stock (the ""Certificate of Designations""). Unless converted pursuant to its terms, the Class A-3 Preferred Stock does not expire. The Certificate of Designations prohibits conversion to the extent that the holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the conversion.",2020-12-04
0001509261,"Rezolute, Inc.",RZLT,0001798101,"HANDOK, INC.","132, TEHERAN-RO",GANGMAN GU,SEOUL,M4,06235,"KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF",0,0,1,0,,,"id=""F1"">The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 6, 2020.",2020-09-30
0001509261,"Rezolute, Inc.",RZLT,0001798101,"HANDOK, INC.","132, TEHERAN-RO",GANGMAN GU,SEOUL,M4,06235,"KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF",0,0,1,0,,,"id=""F2"">The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $0.4299 to $0.44, inclusive.  The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).",2020-09-30
0001509261,"Rezolute, Inc.",RZLT,0001798101,"HANDOK, INC.","132, TEHERAN-RO",GANGMAN GU,SEOUL,M4,06235,"KOREA, DEMOCRATIC PEOPLE'S REPUBLIC OF",0,0,1,0,,,"id=""F3"">The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $0.43 to $0.45, inclusive.  The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2).",2020-09-30
0000908255,BORGWARNER INC,BWA,0001521439,Lissalde Frederic,3850 HAMLIN ROAD,,AUBURN HILLS,MI,48326,,,1,,,President and CEO,,"id=""F1"">Represents shares withheld to cover taxes due upon the vesting of certain restricted stock awards.",2020-02-28
0001710366,CONSOL Energy Inc.,CEIX,0001529381,ROBERSON ED,"1000 CONSOL ENERGY DRIVE, SUITE 100",,CANONSBURG,PA,15317,,1,0,0,0,,,"id=""F1"">Represents a grant of 20,242 restricted stock units pursuant to the Issuer's 2020 Amended and Restated Omnibus Performance Incentive Plan, all of which will vest on May 11, 2021.  Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.",2020-05-11
0001710366,CONSOL Energy Inc.,CEIX,0001529381,ROBERSON ED,"1000 CONSOL ENERGY DRIVE, SUITE 100",,CANONSBURG,PA,15317,,1,0,0,0,,,"id=""F2"">Of the 47,072 shares reported, 20,242 are unvested restricted stock units (including dividend equivalent rights) and 19,376 are vested deferred stock units (including dividend equivalent rights).",2020-05-11
0001555280,Zoetis Inc.,ZTS,0001801162,McFarland James Michael,C/O ZOETIS INC.,10 SYLVAN WAY,PARSIPPANY,NJ,07054,,0,1,0,0,Executive Vice President,,"id=""F1"">These phantom stock units, which were acquired pursuant to the Zoetis Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment fund at any time, provided Zoetis may limit the timing, frequency and permissibility of transfers from one investment fund to another at any time.",2020-10-09
0001555280,Zoetis Inc.,ZTS,0001801162,McFarland James Michael,C/O ZOETIS INC.,10 SYLVAN WAY,PARSIPPANY,NJ,07054,,0,1,0,0,Executive Vice President,,"id=""F2"">Each phantom stock unit represents a fraction of a phantom share of Zoetis common stock, plus a small amount of cash-equivalent investments (the cash-equivalent investments typically represent around 5% of the total value of the phantom stock unit).  Accordingly, the value of each phantom stock unit is determined by reference to the market value of Zoetis common stock and the value of the cash-equivalent investments.",2020-10-09
0000822416,PULTEGROUP INC/MI/,PHM,0001564294,SCHLAGETER STEPHEN P,3350 PEACHTREE ROAD NORTHEAST,SUITE 150,ATLANTA,GA,30326,,,1,,,SVP Operations & Strategy,,"id=""F1"">The price reported is an average weighted price. These shares were sold in multiple transactions at prices ranging from $26.08 to $26.10, inclusive.  The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.",2020-04-27
0000822416,PULTEGROUP INC/MI/,PHM,0001564294,SCHLAGETER STEPHEN P,3350 PEACHTREE ROAD NORTHEAST,SUITE 150,ATLANTA,GA,30326,,,1,,,SVP Operations & Strategy,,"id=""F2"">The price reported is an average weighted price. These shares were sold in multiple transactions at prices ranging from $26.12 to $26.155, inclusive.  The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.",2020-04-27
0000822416,PULTEGROUP INC/MI/,PHM,0001564294,SCHLAGETER STEPHEN P,3350 PEACHTREE ROAD NORTHEAST,SUITE 150,ATLANTA,GA,30326,,,1,,,SVP Operations & Strategy,,"id=""F3"">Represents units of the PulteGroup, Inc. Stock Fund (the Fund) of the PulteGroup, Inc. 401(k) Plan.  The Fund consists of cash and Common Stock in amounts that vary from time to time.  The reporting person's units represent 2,990.679 shares of PulteGroup, Inc. Common Stock held in the Fund as of February 5, 2020.",2020-04-27
0001086222,AKAMAI TECHNOLOGIES INC,AKAM,0001576905,Blumofe Robert,"C/O AKAMAI TECHNOLOGIES, INC.",145 BROADWAY,CAMBRIDGE,MA,02142,,0,1,0,0,EVP Platform & GM Enterprise,,"id=""F1"">Each restricted stock unit (""RSU"") represents the right to receive one share of Akamai common stock upon vesting.",2020-03-01
0001086222,AKAMAI TECHNOLOGIES INC,AKAM,0001576905,Blumofe Robert,"C/O AKAMAI TECHNOLOGIES, INC.",145 BROADWAY,CAMBRIDGE,MA,02142,,0,1,0,0,EVP Platform & GM Enterprise,,"id=""F2"">RSU vests over three years as follows:  1/3 on each of March 1, 2020, 2021 and 2022.",2020-03-01
0000763907,FIRST UNITED CORP/MD/,FUNC,0001609298,Boal Brian R.,19 S. SECOND STREET,,OAKLAND,MD,21550,,1,0,0,0,,,"id=""F1"">The shares were purchased pursuant to a dividend reinvestment program offered through a brokerage account maintained by the reporting person.",2020-11-02
0000789019,MICROSOFT CORP,MSFT,0001626431,Hogan Kathleen T,C/O MICROSOFT CORPORATION,ONE MICROSOFT WAY,REDMOND,WA,98052-6399,,0,1,0,0,"EVP, Human Resources",,"id=""F1"">Represents full vesting of shares earned under a performance stock award granted in September 2017 under the Microsoft Corporation Executive Incentive Plan for the 3-year performance period that ended on June 30, 2020.",2020-08-31
0001564708,NEWS CORP,NWS,0001632944,Pitofsky David B,C/O NEWS CORPORATION,1211 AVENUE OF THE AMERICAS,NEW YORK,NY,10036,,0,1,0,0,General Counsel,,"id=""F1"">Includes dividend equivalents accrued during the performance period that are subject to the same performance-based and time-based vesting conditions as the underlying stock-settled performance stock units.",2020-08-15
0001564708,NEWS CORP,NWS,0001632944,Pitofsky David B,C/O NEWS CORPORATION,1211 AVENUE OF THE AMERICAS,NEW YORK,NY,10036,,0,1,0,0,General Counsel,,"id=""F2"">The stock-settled performance stock units were deemed to have settled for an equivalent number of shares of News Corporation's Class A Common Stock.",2020-08-15
0001564708,NEWS CORP,NWS,0001632944,Pitofsky David B,C/O NEWS CORPORATION,1211 AVENUE OF THE AMERICAS,NEW YORK,NY,10036,,0,1,0,0,General Counsel,,"id=""F3"">Represents shares withheld upon vesting of stock-settled performance stock units to satisfy tax withholding obligation.",2020-08-15
0001564708,NEWS CORP,NWS,0001632944,Pitofsky David B,C/O NEWS CORPORATION,1211 AVENUE OF THE AMERICAS,NEW YORK,NY,10036,,0,1,0,0,General Counsel,,"id=""F4"">Each stock-settled performance stock unit is the economic equivalent of one share of News Corporation's Class A Common Stock.",2020-08-15
0001637459,Kraft Heinz Co,KHC,0001624390,Mulder Susan R,C/O THE KRAFT HEINZ COMPANY,"ONE PPG PLACE, SUITE 3200",PITTSBURGH,PA,15222,,1,0,0,0,,,"id=""F1"">Grant of deferred shares, receipt of which is deferred until the six-month anniversary of the reporting person's separation from service as a director of Kraft Heinz.",2020-05-07
0001517342,PACIFIC DRILLING S.A.,PACD,0001317338,"Avenue Capital Management II, L.P.",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F1"">Collectively, the securities (the ""Common Shares"") reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the ""US Funds"") and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the ""Euro Funds"" and together with the US Funds, the ""Funds"").",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001317338,"Avenue Capital Management II, L.P.",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F2"">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001317338,"Avenue Capital Management II, L.P.",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F3"">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001404730,"Avenue Europe International Management, L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F1"">Collectively, the securities (the ""Common Shares"") reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the ""US Funds"") and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the ""Euro Funds"" and together with the US Funds, the ""Funds"").",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001404730,"Avenue Europe International Management, L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F2"">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001404730,"Avenue Europe International Management, L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F3"">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001798932,"Avenue Europe International Management GenPar, LLC",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F1"">Collectively, the securities (the ""Common Shares"") reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the ""US Funds"") and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the ""Euro Funds"" and together with the US Funds, the ""Funds"").",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001798932,"Avenue Europe International Management GenPar, LLC",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F2"">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001798932,"Avenue Europe International Management GenPar, LLC",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F3"">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001798931,"Avenue-ASRS Europe Opportunities Fund, L.P.",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F1"">Collectively, the securities (the ""Common Shares"") reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the ""US Funds"") and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the ""Euro Funds"" and together with the US Funds, the ""Funds"").",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001798931,"Avenue-ASRS Europe Opportunities Fund, L.P.",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F2"">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001798931,"Avenue-ASRS Europe Opportunities Fund, L.P.",C/O AVENUE CAPITAL GROUP,"11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F3"">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001642372,"Avenue Europe Special Situations Fund III (US), L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F1"">Collectively, the securities (the ""Common Shares"") reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the ""US Funds"") and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the ""Euro Funds"" and together with the US Funds, the ""Funds"").",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001642372,"Avenue Europe Special Situations Fund III (US), L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F2"">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001642372,"Avenue Europe Special Situations Fund III (US), L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F3"">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001642376,"Avenue Europe Special Situations Fund III (Euro), L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F1"">Collectively, the securities (the ""Common Shares"") reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the ""US Funds"") and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the ""Euro Funds"" and together with the US Funds, the ""Funds"").",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001642376,"Avenue Europe Special Situations Fund III (Euro), L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F2"">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001642376,"Avenue Europe Special Situations Fund III (Euro), L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F3"">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001492359,"Avenue Europe Opportunities Master Fund, L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F1"">Collectively, the securities (the ""Common Shares"") reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the ""US Funds"") and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the ""Euro Funds"" and together with the US Funds, the ""Funds"").",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001492359,"Avenue Europe Opportunities Master Fund, L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F2"">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001492359,"Avenue Europe Opportunities Master Fund, L.P.","C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F3"">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001259927,LASRY MARC,"C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F1"">Collectively, the securities (the ""Common Shares"") reported in this Form 4 are held directly by: (i) Avenue Energy Opportunities Fund, L.P., Avenue Energy Opportunities Fund II, L.P., Avenue PPF Opportunities Fund, L.P., Avenue Special Opportunities Fund II, L.P. and Avenue Strategic Opportunities Fund, L.P. (the ""US Funds"") and (ii) Avenue ASRS Europe Opportunities Fund, L.P., Avenue Europe Opportunities Master Fund, L.P., Avenue Europe Special Situations Fund III (Euro), L.P., and Avenue Europe Special Situations Fund III (U.S.), L.P. (the ""Euro Funds"" and together with the US Funds, the ""Funds"").",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001259927,LASRY MARC,"C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F2"">Avenue Capital Management II, L.P. is the investment manager of the US Funds and may be deemed to have voting and dispositive power over the 6,385,765 Common Shares owned by such entities. Avenue Europe International Management, L.P. is the investment manager of the Euro Funds and may be deemed to have voting and dispositive power over the 2,621,757 Common Shares owned by such entities.",2020-06-10
0001517342,PACIFIC DRILLING S.A.,PACD,0001259927,LASRY MARC,"C/O AVENUE CAPITAL GROUP,","11 WEST 42ND STREET, 9TH FLOOR",NEW YORK,NY,10036,,,,true,,,,"id=""F3"">Marc Lasry is the managing member of Avenue Capital Management II GenPar, LLC and Avenue Europe International Management GenPar, LLC. Mr. Lasry may be deemed to be the indirect beneficial owner of the securities reported by the Funds by reason of his ability to direct the vote and/or disposition of such securities, and his pecuniary interest in such shares (within the meaning of Rule 16a-1(a)(2) under the Exchange Act) is a fractional interest in such amount.",2020-06-10
0001653558,"Priority Technology Holdings, Inc.",PRTH,0001747632,Kiewiet Sean,"C/O PRIORITY TECHNOLOGY HOLDINGS, INC.","2001 WESTSIDE PARKWAY, SUITE 155",ALPHARETTA,GA,30004,,0,1,0,0,Chief Technology Officer,,"id=""F1"">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-trading plan adopted by the Reporting Person.",2020-11-09
0001653558,"Priority Technology Holdings, Inc.",PRTH,0001747632,Kiewiet Sean,"C/O PRIORITY TECHNOLOGY HOLDINGS, INC.","2001 WESTSIDE PARKWAY, SUITE 155",ALPHARETTA,GA,30004,,0,1,0,0,Chief Technology Officer,,"id=""F2"">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.73 to $2.92, inclusive. The Reporting Person undertakes to provide to Priority Technology Holdings, Inc., any security holder of Priority Technology Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.",2020-11-09
0001653558,"Priority Technology Holdings, Inc.",PRTH,0001747632,Kiewiet Sean,"C/O PRIORITY TECHNOLOGY HOLDINGS, INC.","2001 WESTSIDE PARKWAY, SUITE 155",ALPHARETTA,GA,30004,,0,1,0,0,Chief Technology Officer,,"id=""F3"">The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $2.67 to $2.75, inclusive. The Reporting Person undertakes to provide to Priority Technology Holdings, Inc., any security holder of Priority Technology Holdings, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.",2020-11-09
0001653653,"Red Rock Resorts, Inc.",RRR,0000942850,FERTITTA LORENZO J,"C/O RED ROCK RESORTS, INC.",1505 SOUTH PAVILION CENTER DRIVE,LAS VEGAS,NV,89135,,1,1,1,0,Vice President,,"id=""F1"">Represents shares of Class A Common Stock acquired by The Lorenzo J. Fertitta and Teresa Jo Fertitta Family Trust (the ""L&T Fertitta Family Trust""), a revocable trust established for the benefit of Lorenzo J. Fertitta and Teresa Jo Fertitta and for which Lorenzo J. Fertitta is co-trustee and has shared investment and voting power.",2020-08-17
0001653653,"Red Rock Resorts, Inc.",RRR,0000942850,FERTITTA LORENZO J,"C/O RED ROCK RESORTS, INC.",1505 SOUTH PAVILION CENTER DRIVE,LAS VEGAS,NV,89135,,1,1,1,0,Vice President,,"id=""F2"">Represents shares of Class A Common Stock acquired by the Frank J. Fertitta, III 2006 Irrevocable Trust (the ""FJF Irrevocable Trust""), an irrevocable trust established for the benefit of Frank J. Fertitta III's three children and for which Lorenzo J. Fertitta is trustee and has sole investment and voting power.",2020-08-17
0001653653,"Red Rock Resorts, Inc.",RRR,0000942850,FERTITTA LORENZO J,"C/O RED ROCK RESORTS, INC.",1505 SOUTH PAVILION CENTER DRIVE,LAS VEGAS,NV,89135,,1,1,1,0,Vice President,,"id=""F3"">Represents a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $16.375 to $16.475.",2020-08-17
0001653653,"Red Rock Resorts, Inc.",RRR,0000942850,FERTITTA LORENZO J,"C/O RED ROCK RESORTS, INC.",1505 SOUTH PAVILION CENTER DRIVE,LAS VEGAS,NV,89135,,1,1,1,0,Vice President,,"id=""F4"">Lorenzo J. Fertitta is a director of the Issuer, and also a beneficial owner of 10% or more of the Issuer's Class A Common Stock (assuming that all of the units of membership interest in Station Holdco LLC (the ""LLC Units"") beneficially owned by Lorenzo J. Fertitta were exchanged for the Issuer's Class A Common Stock) as a result of his ownership interest in FBM Sub 1 LLC (""FBM Sub 1""), Fertitta Business Management LLC (""FBM"") and FI Station Investor LLC (""FI Station"").  The LLC Units are exchangeable at any time and from time to time for an equal number of shares of the Issuer's Class A Common Stock or, at the election of the Issuer, cash.  The LLC Units have no expiration date.",2020-08-17
0001653653,"Red Rock Resorts, Inc.",RRR,0000942850,FERTITTA LORENZO J,"C/O RED ROCK RESORTS, INC.",1505 SOUTH PAVILION CENTER DRIVE,LAS VEGAS,NV,89135,,1,1,1,0,Vice President,,"id=""F5"">FI Station is owned by Fertitta Investment LLC (""Fertitta Investment""), KVF Investments, LLC (""KVF"") and LNA Investments, LLC (""LNA"").  Fertitta Investment is owned by FBM, KVF and LNA.  FI Station and Fertitta Investment are managed by Fertitta Holdco LLC, which is owned and managed by Frank J. Fertitta III and Lorenzo J. Fertitta.  KVF is managed by Frank J. Fertitta III and is beneficially owned by various trusts established for the benefit of his three children.  LNA is managed by Lorenzo J. Fertitta and is beneficially owned by various trusts established for the benefit of his three children.  FBM Sub 1 is owned and controlled by FBM.  FBM is owned and controlled (i) 50% by the F & J Fertitta Family Business Trust (the ""F&J Trust""), a revocable trust for which Frank J. Fertitta III has sole investment and voting power, and (ii) 50% by the L & T Fertitta Family Business Trust (the ""L&T Trust""), a revocable trust for which Lorenzo J. Fertitta has sole investment and voting power.",2020-08-17
0001653653,"Red Rock Resorts, Inc.",RRR,0000942850,FERTITTA LORENZO J,"C/O RED ROCK RESORTS, INC.",1505 SOUTH PAVILION CENTER DRIVE,LAS VEGAS,NV,89135,,1,1,1,0,Vice President,,"id=""F6"">(continued from Footnote 5) Certain Class A Common Stock of the Issuer are held by (i) The Lorenzo J. Fertitta and Teresa Jo Fertitta Family Trust (the ""L&T Fertitta Family Trust""), a revocable trust established for the benefit of Lorenzo J. Fertitta and Teresa Jo Fertitta and for which Lorenzo J. Fertitta is co-trustee and has shared investment and voting power, (ii) the Frank J. Fertitta, III 2006 Irrevocable Trust (the ""FJF Irrevocable Trust""), an irrevocable trust established for the benefit of Frank J. Fertitta III's three children and for which Lorenzo J. Fertitta is trustee and has sole investment and voting power and (iii) the L & T Fertitta Grandchildren's 2020 Irrevocable Trust, an irrevocable trust established for the benefit of the Reporting Person's grandchildren (the ""L&T 2020 Trust"") for which Frank J. Fertitta IV, the Reporting Person's nephew, serves as trustee.",2020-08-17
0001653653,"Red Rock Resorts, Inc.",RRR,0000942850,FERTITTA LORENZO J,"C/O RED ROCK RESORTS, INC.",1505 SOUTH PAVILION CENTER DRIVE,LAS VEGAS,NV,89135,,1,1,1,0,Vice President,,"id=""F7"">(continued from Footnote 6) Based on the Reporting Person's retained right to remove the trustee of the L&T 2020 Trust, the Reporting Person may be deemed to be a beneficial owner of the shares transferred to the L&T 2020 Trust.",2020-08-17
0001653653,"Red Rock Resorts, Inc.",RRR,0000942850,FERTITTA LORENZO J,"C/O RED ROCK RESORTS, INC.",1505 SOUTH PAVILION CENTER DRIVE,LAS VEGAS,NV,89135,,1,1,1,0,Vice President,,"id=""F8"">Lorenzo J. Fertitta disclaims beneficial ownership of any shares of Class A Common Stock or LLC Units beneficially owned by FI Station, Fertitta Investment, FBM Sub 1, FBM, KVF, LNA, the F&J Trust, the L&T Trust, the L&T Fertitta Family Trust, the FJF Irrevocable Trust, and the L&T 2020 Trust, except to the extent of any pecuniary interest therein.",2020-08-17
0001655020,"Extraction Oil & Gas, Inc.",XOG,0001685843,Owens Matthew R,370 17TH STREET,SUITE 5300,DENVER,CO,80202,,1,1,0,0,President & CEO,,"id=""F1"">These shares represent amounts withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations",2020-04-01
0001655020,"Extraction Oil & Gas, Inc.",XOG,0001685843,Owens Matthew R,370 17TH STREET,SUITE 5300,DENVER,CO,80202,,1,1,0,0,President & CEO,,"id=""F2"">These shares are owned by OFI Properties, LLC, of which Mr. Owens holds 100% of the managing interest. The Matthew R. Owens 2016 Grantor Retained Annuity Trust, of which Mr. Owens is Trustee, owns a 75% non-managing interest in OFI Properties, LLC.",2020-04-01
0001076682,"POLARITYTE, INC.",PTE,0001656557,Hague Richard,123 WRIGHT BROTHERS DRIVE,,SALT LAKE CITY,UT,84116,,0,1,0,0,Chf. Oper. Off. & Pres.,,"id=""F1"">The shares were withheld by the Issuer to cover withholding taxes resulting from vesting of restricted stock awards that were previously reported on Table I.",2020-09-28
0000844059,"FRP HOLDINGS, INC.",FRPH,0001664232,deVilliers David H III,200 WEST FORSYTH STREET,7TH FLOOR,JACKSONVILLE,FL,32202,,0,1,0,0,Vice President,,"id=""F1"">Shares were sold pursuant to a 10b5 plan dated June 15, 2020.",2020-09-29
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F1"">These securities are held in the account of Edenbrook Long Only Value Fund, LP, a private fund managed by Edenbrook Capital, LLC and may be deemed to be beneficially owned by Edenbrook Capital, LLC by virtue of its role as the investment manger of such private fund. In addition, Jonathan Brolin may be deemed to be a beneficial owner of such securities by virtue of his role as managing member of Edenbrook Capital, LLC.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F2"">These securities are held in the account of a private fund managed by Edenbrook Capital, LLC and may be deemed to be beneficially owned by Edenbrook Capital, LLC by virtue of its role as the investment manager of such private fund. In addition, Jonathan Brolin may be deemed to be a beneficial owner of such securities by virtue of his role as managing member of Edenbrook Capital, LLC.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F3"">Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F4"">As previously disclosed, Edenbrook Long Only Value Fund, LP wrote 2550, 2550 and 3050 put option contracts expiring in March 2020, June 2020 and September 2020, respectively, which provide that Edenbrook Long Only Value Fund, LP will be required to purchase shares of  common stock at the stated strike price if the counterparty exercises such put options.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F5"">As previously disclosed, a private fund managed by Edenbrook Capital, LLC wrote 450, 450 and 450 put option contracts expiring in  March 2020, June 2020 and September 2020, respectively, which provide that the private fund will be required to purchase shares of common stock at the stated strike price if the counterparty exercises such put options.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F6"">As previously disclosed, Edenbrook Long Only Value Fund, LP  bought 425 call option contracts expiring in June 2020 which provide that Edenbrook Long Only Value Fund, LP will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F7"">As previously disclosed, a private fund managed by Edenbrook Capital, LLC  bought 75 call option contracts expiring in June 2020 which provide that the private fund will have the right to purchase shares of common stock at the stated price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F8"">Edenbrook Long Only Value Fund, LP wrote 2200 put option contracts expiring in December 2020 which provide that Edenbrook Long Only Value Fund, LP will be required to purchase shares of common stock at the stated  strike price if the counterparty exercises such put option.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F9"">A private fund managed by Edenbrook Capital, LLC wrote 300 put option contracts expiring in December 2020 which provide that the private fund will be required to purchase shares of common stock at the stated strike price if the counterparty exercises such put option.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F10"">Edenbrook Long Only Value Fund, LP bought 2200 call option contracts expiring in June 2020 which provide that Edenbrook Long Only Value Fund, LP will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F11"">A private fund managed by Edenbrook Capital, LLC bought 300 call option contracts expiring in June 2020 which provide that the private fund will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001666682,"Edenbrook Capital, LLC",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F12"">Price shown equals per share option premium.  Each contract represents 100 shares.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F1"">These securities are held in the account of Edenbrook Long Only Value Fund, LP, a private fund managed by Edenbrook Capital, LLC and may be deemed to be beneficially owned by Edenbrook Capital, LLC by virtue of its role as the investment manger of such private fund. In addition, Jonathan Brolin may be deemed to be a beneficial owner of such securities by virtue of his role as managing member of Edenbrook Capital, LLC.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F2"">These securities are held in the account of a private fund managed by Edenbrook Capital, LLC and may be deemed to be beneficially owned by Edenbrook Capital, LLC by virtue of its role as the investment manager of such private fund. In addition, Jonathan Brolin may be deemed to be a beneficial owner of such securities by virtue of his role as managing member of Edenbrook Capital, LLC.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F3"">Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F4"">As previously disclosed, Edenbrook Long Only Value Fund, LP wrote 2550, 2550 and 3050 put option contracts expiring in March 2020, June 2020 and September 2020, respectively, which provide that Edenbrook Long Only Value Fund, LP will be required to purchase shares of  common stock at the stated strike price if the counterparty exercises such put options.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F5"">As previously disclosed, a private fund managed by Edenbrook Capital, LLC wrote 450, 450 and 450 put option contracts expiring in  March 2020, June 2020 and September 2020, respectively, which provide that the private fund will be required to purchase shares of common stock at the stated strike price if the counterparty exercises such put options.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F6"">As previously disclosed, Edenbrook Long Only Value Fund, LP  bought 425 call option contracts expiring in June 2020 which provide that Edenbrook Long Only Value Fund, LP will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F7"">As previously disclosed, a private fund managed by Edenbrook Capital, LLC  bought 75 call option contracts expiring in June 2020 which provide that the private fund will have the right to purchase shares of common stock at the stated price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F8"">Edenbrook Long Only Value Fund, LP wrote 2200 put option contracts expiring in December 2020 which provide that Edenbrook Long Only Value Fund, LP will be required to purchase shares of common stock at the stated  strike price if the counterparty exercises such put option.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F9"">A private fund managed by Edenbrook Capital, LLC wrote 300 put option contracts expiring in December 2020 which provide that the private fund will be required to purchase shares of common stock at the stated strike price if the counterparty exercises such put option.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F10"">Edenbrook Long Only Value Fund, LP bought 2200 call option contracts expiring in June 2020 which provide that Edenbrook Long Only Value Fund, LP will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F11"">A private fund managed by Edenbrook Capital, LLC bought 300 call option contracts expiring in June 2020 which provide that the private fund will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001665975,"EDENBROOK LONG ONLY VALUE FUND, LP",116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F12"">Price shown equals per share option premium.  Each contract represents 100 shares.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F1"">These securities are held in the account of Edenbrook Long Only Value Fund, LP, a private fund managed by Edenbrook Capital, LLC and may be deemed to be beneficially owned by Edenbrook Capital, LLC by virtue of its role as the investment manger of such private fund. In addition, Jonathan Brolin may be deemed to be a beneficial owner of such securities by virtue of his role as managing member of Edenbrook Capital, LLC.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F2"">These securities are held in the account of a private fund managed by Edenbrook Capital, LLC and may be deemed to be beneficially owned by Edenbrook Capital, LLC by virtue of its role as the investment manager of such private fund. In addition, Jonathan Brolin may be deemed to be a beneficial owner of such securities by virtue of his role as managing member of Edenbrook Capital, LLC.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F3"">Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F4"">As previously disclosed, Edenbrook Long Only Value Fund, LP wrote 2550, 2550 and 3050 put option contracts expiring in March 2020, June 2020 and September 2020, respectively, which provide that Edenbrook Long Only Value Fund, LP will be required to purchase shares of  common stock at the stated strike price if the counterparty exercises such put options.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F5"">As previously disclosed, a private fund managed by Edenbrook Capital, LLC wrote 450, 450 and 450 put option contracts expiring in  March 2020, June 2020 and September 2020, respectively, which provide that the private fund will be required to purchase shares of common stock at the stated strike price if the counterparty exercises such put options.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F6"">As previously disclosed, Edenbrook Long Only Value Fund, LP  bought 425 call option contracts expiring in June 2020 which provide that Edenbrook Long Only Value Fund, LP will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F7"">As previously disclosed, a private fund managed by Edenbrook Capital, LLC  bought 75 call option contracts expiring in June 2020 which provide that the private fund will have the right to purchase shares of common stock at the stated price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F8"">Edenbrook Long Only Value Fund, LP wrote 2200 put option contracts expiring in December 2020 which provide that Edenbrook Long Only Value Fund, LP will be required to purchase shares of common stock at the stated  strike price if the counterparty exercises such put option.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F9"">A private fund managed by Edenbrook Capital, LLC wrote 300 put option contracts expiring in December 2020 which provide that the private fund will be required to purchase shares of common stock at the stated strike price if the counterparty exercises such put option.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F10"">Edenbrook Long Only Value Fund, LP bought 2200 call option contracts expiring in June 2020 which provide that Edenbrook Long Only Value Fund, LP will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F11"">A private fund managed by Edenbrook Capital, LLC bought 300 call option contracts expiring in June 2020 which provide that the private fund will have the right to purchase shares of common stock at the stated strike price.",2020-02-11
0001224133,MARCHEX INC,MCHX,0001712127,Brolin Jonathan,116 RADIO CIRCLE,SUITE 202,MOUNT KISCO,NY,10549,,0,0,1,0,,,"id=""F12"">Price shown equals per share option premium.  Each contract represents 100 shares.",2020-02-11
0001681459,TechnipFMC plc,FTI,0001776231,Piou Olivier,C/O TECHNIPFMC PLC,ONE ST. PAUL'S CHURCHYARD,LONDON,X0,EC4M 8AP,UNITED KINGDOM,1,0,0,0,,,"id=""F1"">Represents the weighted average trading price (EUR 13.70) of the shares purchased on the Euronext Paris Exchange based on an exchange rate of EUR 1 to USD 1.1026 on the date of the transaction.  The trading range for these shares was EUR 13.50 to EUR 14.00.  The reporting person will provide full information regarding the number of shares sold at each separate price upon request by the Securities Exchange Commission, the Issuer, or a security holder of the Issuer.",2020-02-28
0001517175,"Chefs' Warehouse, Inc.",CHEF,0001686807,Leddy James,100 EAST RIDGE ROAD,,RIDGEFIELD,CT,06877,,0,1,0,0,Chief Financial Officer,,"id=""F1"">Shares withheld upon vesting of restricted common stock awarded to reporting person pursuant to The Chefs' Warehouse 2019 Omnibus Equity Incentive Plan (the ""Plan"").",2020-02-25
0001517175,"Chefs' Warehouse, Inc.",CHEF,0001686807,Leddy James,100 EAST RIDGE ROAD,,RIDGEFIELD,CT,06877,,0,1,0,0,Chief Financial Officer,,"id=""F2"">The reporting person received 9,656 shares of restricted common stock pursuant to the Plan. The forfeiture restrictions associated with this award will lapse in one-third increments as of the first through third anniversary dates of the grant date, February 25, 2020.",2020-02-25
0001692819,Vistra Corp.,VST,0001703634,Moore Stephanie Zapata,6555 SIERRA DRIVE,,IRVING,TX,75039,,0,1,0,0,EVP and General Counsel,,"id=""F1"">This transaction represents the withholding by the Issuer of shares to pay taxes in connection with the vesting of restricted stock units. The timing and amount of the transaction were determined by the terms of the applicable restricted stock unit award and were not within the control of the Reporting Person.",2020-10-02
0001701114,"Blue Apron Holdings, Inc.",APRN,0001607393,Deutsch Meredith L,"C/O BLUE APRON HOLDINGS, INC.",28 LIBERTY STREET,NEW YORK,NY,10005,,0,1,0,0,General Counsel & Corp. Sec'y,,"id=""F1"">Restricted stock units (""RSUs"") convert into Class A Common Stock on a one-for-one basis.  This transaction represents the settlement of RSUs in shares of Class A Common Stock on their scheduled vesting date.",2020-08-25
0001701114,"Blue Apron Holdings, Inc.",APRN,0001607393,Deutsch Meredith L,"C/O BLUE APRON HOLDINGS, INC.",28 LIBERTY STREET,NEW YORK,NY,10005,,0,1,0,0,General Counsel & Corp. Sec'y,,"id=""F2"">Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the RSUs listed in Table II. This sale does not represent a discretionary trade by the reporting person.",2020-08-25
0001701114,"Blue Apron Holdings, Inc.",APRN,0001607393,Deutsch Meredith L,"C/O BLUE APRON HOLDINGS, INC.",28 LIBERTY STREET,NEW YORK,NY,10005,,0,1,0,0,General Counsel & Corp. Sec'y,,"id=""F3"">Represents the weighted average sale price for shares sold in multiple transactions. Sale prices ranged from $7.5550 to $7.5700 per share. Upon request of the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.",2020-08-25
0001701114,"Blue Apron Holdings, Inc.",APRN,0001607393,Deutsch Meredith L,"C/O BLUE APRON HOLDINGS, INC.",28 LIBERTY STREET,NEW YORK,NY,10005,,0,1,0,0,General Counsel & Corp. Sec'y,,"id=""F4"">On February 26, 2020, the reporting person was granted 6,667 RSUs, scheduled to vest over four years in quarterly installments, with 6.25% of the RSUs vesting on each May 25, August 25, November 25 and February 25 over the four-year period following February 26, 2020.",2020-08-25
0001701114,"Blue Apron Holdings, Inc.",APRN,0001607393,Deutsch Meredith L,"C/O BLUE APRON HOLDINGS, INC.",28 LIBERTY STREET,NEW YORK,NY,10005,,0,1,0,0,General Counsel & Corp. Sec'y,,"id=""F5"">On May 25, 2020, the reporting person was granted 6,667 RSUs, scheduled to vest over four years in quarterly installments, with 6.25% of the RSUs vesting on each August 25, November 25, February 25 and May 25 over the four-year period following May 25, 2020.",2020-08-25
0001701114,"Blue Apron Holdings, Inc.",APRN,0001607393,Deutsch Meredith L,"C/O BLUE APRON HOLDINGS, INC.",28 LIBERTY STREET,NEW YORK,NY,10005,,0,1,0,0,General Counsel & Corp. Sec'y,,"id=""F6"">On August 25, 2020, the reporting person was granted 6,667 RSUs, with 12.5% of the RSUs scheduled to vest on each of November 25, 2020 and February 25, 2021 and the remainder scheduled to vest thereafter in quarterly installments with 6.25% of the remainder vesting on each November 25, February 25, May 25 and August 25 thereafter over the four-year period beginning on May 25, 2021.",2020-08-25
0001691337,PCSB Financial Corp,PCSB,0001703752,Weiss Richard F.,"2651 STRANG BOULEVARD, SUITE 100",,YORKTOWN HEIGHTS,NY,10598,,1,0,0,0,,,"id=""F1"">Includes shares of restricted stock which vest at a rate of 20% per year commencing on October 24, 2019.",2020-08-28
0001691337,PCSB Financial Corp,PCSB,0001703752,Weiss Richard F.,"2651 STRANG BOULEVARD, SUITE 100",,YORKTOWN HEIGHTS,NY,10598,,1,0,0,0,,,"id=""F2"">Stock options vest at a rate of 20% per year commencing on October 24, 2019.",2020-08-28
0001691337,PCSB Financial Corp,PCSB,0001703752,Weiss Richard F.,"2651 STRANG BOULEVARD, SUITE 100",,YORKTOWN HEIGHTS,NY,10598,,1,0,0,0,,,"id=""F3"">Each share of phantom stock is the economic equivalent of one share of common stock and becomes payable upon the reporting person's termination of service as a director.",2020-08-28
0000766421,"ALASKA AIR GROUP, INC.",ALK,0001715974,SCHNEIDER ANDREA L,19300 INTERNATIONAL BLVD,,SEATTLE,WA,98188,,false,true,false,false,SR VP PEOPLE,,"id=""F1"">OPTIONS VEST IN EQUAL INSTALLMENTS ON THE FIRST THREE ANNIVERSARIES OF THE GRANT DATE (11/5/2021, 11/5/2022 AND 11/5/2023).",
0000766421,"ALASKA AIR GROUP, INC.",ALK,0001715974,SCHNEIDER ANDREA L,19300 INTERNATIONAL BLVD,,SEATTLE,WA,98188,,false,true,false,false,SR VP PEOPLE,,"id=""F2"">RESTRICTED STOCK UNITS WILL VEST ANNUALLY IN EQUAL INSTALLMENTS ON THE FIRST THREE ANNIVERSARIES OF THE GRANT DATE AND CONVERT INTO COMMON STOCK ON A ONE-FOR-ONE-BASIS.",
0001717452,"Odonate Therapeutics, Inc.",ODT,0001723966,O'Connell Joseph P,"C/O ODONATE THERAPEUTICS, INC.","4747 EXECUTIVE DRIVE, SUITE 210",SAN DIEGO,CA,92121,,0,1,0,0,Chief Medical Officer,,"id=""F1"">These shares were acquired on 07/15/2020 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).",2020-07-15
0001717452,"Odonate Therapeutics, Inc.",ODT,0001723966,O'Connell Joseph P,"C/O ODONATE THERAPEUTICS, INC.","4747 EXECUTIVE DRIVE, SUITE 210",SAN DIEGO,CA,92121,,0,1,0,0,Chief Medical Officer,,"id=""F2"">The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration (""FDA"") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.",2020-07-15
0001285550,"ClearPoint Neuro, Inc.",CLPT,0001721010,BURNETT JOSEPH MICHAEL,"C/O CLEARPOINT NEURO, INC.",5 MUSICK,IRVINE,CA,92618,,1,1,0,0,CEO and President,,"id=""F1"">Represents the amount of shares delivered to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock",2020-05-07
0001729427,"CNS Pharmaceuticals, Inc.",CNSP,0001792732,Andraczke Andrzej,"C/O CNS PHARMACEUTICALS, INC.","100 WEST LOOP SOUTH, SUITE 900",HOUSTON,TX,77027,,1,0,0,0,,,"id=""F1"">The stock options set forth in this table vest on the earlier of the one-year anniversary of the issuance date or the date of the 2021 annual meeting, subject to the grantee's continued service to the Company on the vesting date.",2020-06-12
0001729427,"CNS Pharmaceuticals, Inc.",CNSP,0001792732,Andraczke Andrzej,"C/O CNS PHARMACEUTICALS, INC.","100 WEST LOOP SOUTH, SUITE 900",HOUSTON,TX,77027,,1,0,0,0,,,"id=""F2"">The stock options were issued in connection with the reporting person's Board of Director services to the Company.",2020-06-12
0001341317,Bridgewater Bancshares Inc,BWB,0001733121,Juran David B.,"C/O BRIDGEWATER BANCSHARES, INC.","4450 EXCELSIOR BLVD., SUITE 100",ST. LOUIS PARK,MN,55416,,1,0,0,0,,,"id=""F1"">The price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.60 to $9.70, inclusive. The reporting person undertakes to provide Bridgewater Bancshares, Inc., any security holder of Bridgewater Bancshares, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price set forth in this footnote to this Form 4.",2020-09-01
0001341317,Bridgewater Bancshares Inc,BWB,0001733121,Juran David B.,"C/O BRIDGEWATER BANCSHARES, INC.","4450 EXCELSIOR BLVD., SUITE 100",ST. LOUIS PARK,MN,55416,,1,0,0,0,,,"id=""F2"">Shares of common stock are held by Mr. Juran as co-trustee of a Marital Trust dated June 18, 2002. Mr. Juran possesses shared voting and investment power with respect to the shares of common stock held under the trust.",2020-09-01
0001341317,Bridgewater Bancshares Inc,BWB,0001733121,Juran David B.,"C/O BRIDGEWATER BANCSHARES, INC.","4450 EXCELSIOR BLVD., SUITE 100",ST. LOUIS PARK,MN,55416,,1,0,0,0,,,"id=""F3"">Shares of common stock are held by Mr. Juran as co-trustee of a Residuary Trust dated June 18, 2002. Mr. Juran possesses shared voting and investment power with respect to the shares of common stock held under the trust.",2020-09-01
0001341317,Bridgewater Bancshares Inc,BWB,0001733285,Johnson James S.,"C/O BRIDGEWATER BANCSHARES, INC.","3800 AMERICAN BLVD WEST, SUITE 100",BLOOMINGTON,MN,55431,,1,0,0,0,,,"id=""F1"">Shares of common stock are held by Mr. Johnson as co-trustee of the James S. Johnson Trust, dated May 28, 2015. Mr. Johnson possesses shared voting and investment power with respect to the shares of common stock held under the James S. Johnson Trust dated May 28, 2015.",2020-06-30
0001341317,Bridgewater Bancshares Inc,BWB,0001733285,Johnson James S.,"C/O BRIDGEWATER BANCSHARES, INC.","3800 AMERICAN BLVD WEST, SUITE 100",BLOOMINGTON,MN,55431,,1,0,0,0,,,"id=""F2"">Shares of common stock are held by Mr. Johnson as co-trustee of the Jolynn Johnson Trust dated May 28, 2015. Mr. Johnson possesses shared voting and investment power with respect to the shares of common stock held under the Jolynn Johnson Trust dated May 28, 2015.",2020-06-30
0001737287,"Allogene Therapeutics, Inc.",ALLO,0001754937,MOORE ALISON,210 EAST GRAND AVENUE,,SOUTH SAN FRANCISCO,CA,94080,,false,true,false,false,Chief Technical Officer,,"id=""F1"">The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in June 2020.",2020-10-12
0001737287,"Allogene Therapeutics, Inc.",ALLO,0001754937,MOORE ALISON,210 EAST GRAND AVENUE,,SOUTH SAN FRANCISCO,CA,94080,,false,true,false,false,Chief Technical Officer,,"id=""F2"">One-fourth of the 892,500 shares subject to the stock option vested on June 1, 2019, and the remaining shares vest in 36 successive equal monthly installments thereafter.",2020-10-12
0001346302,XERIS PHARMACEUTICALS INC,XERS,0001744027,PRESTRELSKI STEVEN,"C/O XERIS PHARMACEUTICALS, INC.","180 N. LASALLE STREET, SUITE 1600",CHICAGO,IL,60601,,0,1,0,0,Chief Scientific Officer,,"id=""F1"">These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These restricted stock units vest in three substantially equal annual installments beginning on January 31, 2021.",2020-01-31
0001759509,"Lyft, Inc.",LYFT,0001760231,Makavy Ran I.,"C/O LYFT, INC.","185 BERRY STREET, SUITE 5000",SAN FRANCISCO,CA,94107,,0,1,0,0,EVP and Chief Product Officer,,"id=""F1"">The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.",2020-02-26
0001759509,"Lyft, Inc.",LYFT,0001760231,Makavy Ran I.,"C/O LYFT, INC.","185 BERRY STREET, SUITE 5000",SAN FRANCISCO,CA,94107,,0,1,0,0,EVP and Chief Product Officer,,"id=""F2"">This transaction was executed in multiple trades at prices ranging from $40.00 to $40.98. The price reported above reflects the weighted average sale price.
The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.",2020-02-26
0001759509,"Lyft, Inc.",LYFT,0001760231,Makavy Ran I.,"C/O LYFT, INC.","185 BERRY STREET, SUITE 5000",SAN FRANCISCO,CA,94107,,0,1,0,0,EVP and Chief Product Officer,,"id=""F3"">Certain of these securities are restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each restricted stock unit.",2020-02-26
0001759509,"Lyft, Inc.",LYFT,0001760231,Makavy Ran I.,"C/O LYFT, INC.","185 BERRY STREET, SUITE 5000",SAN FRANCISCO,CA,94107,,0,1,0,0,EVP and Chief Product Officer,,"id=""F4"">This transaction was executed in multiple trades at prices ranging from $41.00 to $41.96. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.",2020-02-26
0000028412,COMERICA INC /NEW/,CMA,0001763219,OBERG JAY K.,1717 MAIN STREET,MC 6406,DALLAS,TX,75201,,0,1,0,0,EVP - Chief Risk Officer,,"id=""F1"">Includes shares acquired through employee stock plans, shares purchased with reinvested dividends and restricted stock units as of January 24, 2020.",2020-01-24
0000028412,COMERICA INC /NEW/,CMA,0001763219,OBERG JAY K.,1717 MAIN STREET,MC 6406,DALLAS,TX,75201,,0,1,0,0,EVP - Chief Risk Officer,,"id=""F2"">Includes shares acquired through employee stock plans, shares purchased with reinvested dividends and restricted stock units as of January 26, 2020.",2020-01-24
0000028412,COMERICA INC /NEW/,CMA,0001763219,OBERG JAY K.,1717 MAIN STREET,MC 6406,DALLAS,TX,75201,,0,1,0,0,EVP - Chief Risk Officer,,"id=""F3"">Includes shares acquired through employee stock plans, shares purchased with reinvested dividends and restricted stock units as of January 27, 2020.",2020-01-24
0000028412,COMERICA INC /NEW/,CMA,0001763219,OBERG JAY K.,1717 MAIN STREET,MC 6406,DALLAS,TX,75201,,0,1,0,0,EVP - Chief Risk Officer,,"id=""F4"">The options vest in four equal annual installments (based on the original grant amount) beginning on the date indicated in this column.",2020-01-24
0001476150,Terreno Realty Corp,TRNO,0001767760,Lee David M,C/O TERRENO REALTY CORPORATION,"101 MONTGOMERY STREET, SUITE 200",SAN FRANCISCO,CA,94104,,1,0,0,0,,,"id=""F1"">The reporting person elected to defer receipt of 1,865 shares of shares of common stock of the Company pursuant to the Terreno Realty Corporation Deferred Compensation Plan.",
0001348036,"AVALARA, INC.",AVLR,0001770686,Mathradas Amit,255 SOUTH KING ST.,SUITE 1800,SEATTLE,WA,98104,,0,1,0,0,See Remarks,,"id=""F1"">This prearranged sale was effected pursuant to a written authorization executed by the Reporting Person on September 11, 2019, and represents shares required to be sold to cover tax withholding obligations in connection with the vesting of restricted stock units.",2020-04-06
0001679363,"Morphic Holding, Inc.",MORF,0001780270,DeVaul William,"C/O MORPHIC HOLDING, INC.","35 GATEHOUSE DRIVE, A2",WALTHAM,MA,02451,,0,1,0,0,General Counsel and Secretary,,"id=""F1"">The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.",2020-07-07
0001679363,"Morphic Holding, Inc.",MORF,0001780270,DeVaul William,"C/O MORPHIC HOLDING, INC.","35 GATEHOUSE DRIVE, A2",WALTHAM,MA,02451,,0,1,0,0,General Counsel and Secretary,,"id=""F2"">The reported price in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $25.42 to $26.28 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.",2020-07-07
0001679363,"Morphic Holding, Inc.",MORF,0001780270,DeVaul William,"C/O MORPHIC HOLDING, INC.","35 GATEHOUSE DRIVE, A2",WALTHAM,MA,02451,,0,1,0,0,General Counsel and Secretary,,"id=""F3"">The reported price in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $24.38 to $25.36 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.",2020-07-07
0001679363,"Morphic Holding, Inc.",MORF,0001780270,DeVaul William,"C/O MORPHIC HOLDING, INC.","35 GATEHOUSE DRIVE, A2",WALTHAM,MA,02451,,0,1,0,0,General Counsel and Secretary,,"id=""F4"">The reported price in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $25.54 to $26.11 per share, inclusive.  The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.",2020-07-07
0001679363,"Morphic Holding, Inc.",MORF,0001780270,DeVaul William,"C/O MORPHIC HOLDING, INC.","35 GATEHOUSE DRIVE, A2",WALTHAM,MA,02451,,0,1,0,0,General Counsel and Secretary,,"id=""F5"">The option vests as to 2.0833% of the total shares monthly, beginning October 30, 2018, with 100% of the total shares vested and exercisable on September 30, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.",2020-07-07
0001772921,OneWater Marine Inc.,ONEW,0001789635,Singleton Philip Austin Jr.,6275 LANIER ISLANDS PARKWAY,,BUFORD,GA,30518,,true,true,,,Chief Executive Officer,,"id=""F1"">At the request of the holder, each Common Unit of One Water Marine Holdings, LLC (""OneWater LLC"")  may be coupled with a share of Class B common stock and redeemed for, at the Issuer's election and subject to certain restrictions in the Fourth Amended and Restated Limited Liability Company Agreement of OneWater LLC (the ""OneWater LLC Agreement""), newly-issued shares of Class A common stock of OneWater Marine Inc. on a one-for-one basis or for a cash payment to be determined pursuant to the OneWater LLC Agreement for each Common Unit redeemed. The Common Units do not expire.",2020-09-22
0001772921,OneWater Marine Inc.,ONEW,0001789635,Singleton Philip Austin Jr.,6275 LANIER ISLANDS PARKWAY,,BUFORD,GA,30518,,true,true,,,Chief Executive Officer,,"id=""F2"">Pursuant to the OneWater LLC Agreement,  the shares of the Issuer's Class B common stock were cancelled for no consideration on a one-for-one basis upon the redemption by the Reporting Person of OneWater LLC common units, together with a corresponding number of shares of Class B common stock, for shares of the Issuer's Class A common stock.",2020-09-22
0001275014,"Ultra Clean Holdings, Inc.",UCTT,0001791106,Cho Paul Yoonku,"ULTRA CLEAN HOLDINGS, INC.",26462 CORPORATE AVENUE,HAYWARD,CA,94545,,0,1,0,0,General Counsel and Secretary,,"id=""F1"">Represents shares automatically withheld for payment of tax liability arising as a result of the partial settlement of restricted stock unit awards that vested.",2020-10-25
0001372183,"Monaker Group, Inc.",MKGI,0001792658,Zubko Alexandra Charters,2893 EXECUTIVE PARK DRIVE,SUITE 201,WESTON,FL,33331,,1,0,0,0,,,"id=""F1"">Issued in consideration for service on the Board of Directors for a portion of the quarter ended February 29, 2020. Approved by the Compensation Committee and the Board of Directors, and granted under the registrant's 2017 Equity Incentive Plan, as amended. Exempt pursuant to Rule 16b3(d).",2020-03-02
0000866706,ESCO TECHNOLOGIES INC,ESE,0001794684,Valdez Gloria L,C/O ESCO TECHNOLOGIES INC,9900 A CLAYTON ROAD,ST LOUIS,MO,63124,,1,0,0,0,,,"id=""F1"">Common Stock Equivalents issued in lieu of cash dividends on the Common Stock Equivalents held by the director on the record date. Each Common Stock Equivalent is the economic equivalent of one share of common stock. The Common Stock Equivalents become payable in common stock upon, or at the election of the reporting person in installments beginning upon, the termination of the reporting person's service as a director or such earlier time as the director may  have designated.",2020-04-17
0001321732,Penumbra Inc,PEN,0001796068,Shiu Lambert,ONE PENUMBRA PLACE,,ALAMEDA,CA,94502,,0,1,0,0,Chief Accounting Officer,,"id=""F1"">Shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of Restricted Stock Units granted to the Reporting Person.",2020-10-15
0001321732,Penumbra Inc,PEN,0001796068,Shiu Lambert,ONE PENUMBRA PLACE,,ALAMEDA,CA,94502,,0,1,0,0,Chief Accounting Officer,,"id=""F2"">A portion of these shares is subject to vesting.",2020-10-15
0001321732,Penumbra Inc,PEN,0001796068,Shiu Lambert,ONE PENUMBRA PLACE,,ALAMEDA,CA,94502,,0,1,0,0,Chief Accounting Officer,,"id=""F3"">Shares are held by the Reporting Person's spouse in an IRA.",2020-10-15
0000764478,BEST BUY CO INC,BBY,0001797374,Alexander Whitney L,7601 PENN AVENUE S.,,RICHFIELD,MN,55423,,,1,,,Chief Transformation Officer,,"id=""F1"">Represents the vesting and share settlement of a performance share award approved by the Issuer on March 13, 2017. Performance for this award was measured based on the Issuer's total shareholder return (TSR) compared to the TSR of the companies within the S&P 500 Index, over the 36-month period commencing on January 29, 2017, and ending on February 1, 2020. The performance results and number of shares earned based on the results were approved by the Compensation and Human Resources Committee of the Board of Directors on May 20, 2020.",2020-05-20
0000101382,UMB FINANCIAL CORP,UMBF,0001801742,Odgers David Carl,1010 GRAND BOULEVARD,,KANSAS CITY,MO,64106,,,1,,,Chief Accounting Officer,,"id=""F1"">The restricted stock units vest 50% on 2/11/22, 75% on 2/11/23 and 100% on 2/11/24.",2020-02-11
0000019411,MAGELLAN HEALTH INC,MGLN,0001244921,WEST JEFFREY N,14100  MAGELLAN PLAZA,,MARYLAND HEIGHTS,MO,63043,,0,1,0,0,SVP & Controller,,"id=""F1"">Not applicable.",2020-03-04
0000019411,MAGELLAN HEALTH INC,MGLN,0001244921,WEST JEFFREY N,14100  MAGELLAN PLAZA,,MARYLAND HEIGHTS,MO,63043,,0,1,0,0,SVP & Controller,,"id=""F2"">On the third anniversary of the grant date, Performance-Based Restricted Stock Units (""PSUs"") vest based on achievement of total shareholder return (""TSR"") performance relative to the S&P Health Services Industry Index over a three-year period beginning in 2020 and ending in 2022. Payout for vested PSUs ranges from 0% to 200% of the indicated number of shares, based on the Company's TSR percentile ranking compared to the TSR of the companies included in the selected market index. TSR is measured generally as the increase or decrease in the market value of the Company common stock with a deemed reinvestment of any dividends. If a participant terminates employment prior to the third anniversary of the grant date, the PSUs generally will be forfeited. PSUs have no voting rights and are generally non-transferable.  The indicated number of PSUs assumes 100% vesting, and the actual number of shares issued in settlement of the PSUs may be greater or less than the indicated number.",2020-03-04
0000019411,MAGELLAN HEALTH INC,MGLN,0001244921,WEST JEFFREY N,14100  MAGELLAN PLAZA,,MARYLAND HEIGHTS,MO,63043,,0,1,0,0,SVP & Controller,,"id=""F3"">(Continuation of Footnote 3) - Since the payout for PSUs can range from 0% to 200%, the maximum number of shares that could vest and be issued could be double the indicated number.",2020-03-04
0000019411,MAGELLAN HEALTH INC,MGLN,0001244921,WEST JEFFREY N,14100  MAGELLAN PLAZA,,MARYLAND HEIGHTS,MO,63043,,0,1,0,0,SVP & Controller,,"id=""F4"">Restricted Stock Units vest in one third increments on March 4th of each of 2021, 2022 and 2023.",2020-03-04
0000021535,COHU INC,COHU,0001184552,BENDUSH WILLIAM,12367 CROSTHWAITE CIRCLE,,POWAY,CA,92064,,1,0,0,0,,,"id=""F1"">The shares with respect to this transaction were sold in multiple trades at prices ranging from $15.190 to $15.525; the price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.",2020-05-21
0000021535,COHU INC,COHU,0001184552,BENDUSH WILLIAM,12367 CROSTHWAITE CIRCLE,,POWAY,CA,92064,,1,0,0,0,,,"id=""F2"">Number of shares includes 8,532 Restricted Stock Units (RSUs) previously reported that in the future will be converted on a one-for-one basis into shares of Cohu, Inc. Common Stock immediately upon the vesting date (assuming continued service to the Board of Directors).",2020-05-21
0000023197,COMTECH TELECOMMUNICATIONS CORP /DE/,CMTL,0001516592,Waldman Lawrence,"68 SOUTH SERVICE ROAD, SUITE 230",,MELVILLE,NY,11747,,1,0,0,0,,,"id=""F1"">Restricted stock awards were granted under the Company's 2000 Stock Incentive Plan, and represent the right to receive one share of common stock of Comtech Telecommunications Corp. upon vesting.",2020-08-04
0000023197,COMTECH TELECOMMUNICATIONS CORP /DE/,CMTL,0001516592,Waldman Lawrence,"68 SOUTH SERVICE ROAD, SUITE 230",,MELVILLE,NY,11747,,1,0,0,0,,,"id=""F2"">Generally, the restricted stock awards will vest in installments over a five year period, at a rate of 20% on the first through fifth anniversaries of grant, assuming continued service as a director. Shares of common stock corresponding to vested awards will be delivered to the reporting person within 30 days of vesting.",2020-08-04
0001655888,Owl Rock Capital Corp,ORCC,0000315054,REGENTS OF THE UNIVERSITY OF CALIFORNIA,"1111 BROADWAY, SUITE 2100",,OAKLAND,CA,94607,,,,true,,,,"id=""F1"">The price is a weighted average of the multiple trades that took place on 5/11/2020. The lowest price at which the shares were sold was $12.50 and the highest price was $12.685.",2020-05-11
0000354707,HAWAIIAN ELECTRIC INDUSTRIES INC,HE,0001470009,OSHIMA ALAN M.,P.O. BOX 730,,HONOLULU,HI,96808-0730,,0,1,0,0,"SR Exec Advisor, Hawn Electric",,"id=""F1"">Transfer of shares to Trust Account.",2020-03-03
0000354707,HAWAIIAN ELECTRIC INDUSTRIES INC,HE,0001470009,OSHIMA ALAN M.,P.O. BOX 730,,HONOLULU,HI,96808-0730,,0,1,0,0,"SR Exec Advisor, Hawn Electric",,"id=""F2"">Includes accrued dividend equivalents (as denominated in shares of HE common stock) from January 31, 2017 (first RSU grants in 2017) to date.  Dividend equivalents accrue in HE common stock with respect to outstanding RSUs when and as dividends are paid.  Accrued dividend equivalents are denominated in HE common stock and paid upon vesting in shares of HE common stock.",2020-03-03
0000354707,HAWAIIAN ELECTRIC INDUSTRIES INC,HE,0001470009,OSHIMA ALAN M.,P.O. BOX 730,,HONOLULU,HI,96808-0730,,0,1,0,0,"SR Exec Advisor, Hawn Electric",,"id=""F3"">Includes shares acquired under the Hawaiian Electric Industries, Inc. Dividend Reinvestment and Stock Purchase Plan.",2020-03-03
0000066570,MSA Safety Inc,MSA,0001547529,Blanco Steven C. Sr.,1000 CRANBERRY WOODS DRIVE,,CRANBERRY WOODS TOWNSHIP,PA,16066,,,1,,,Vice President,,"id=""F1"">Share price on this transaction ranged from $143.68 to $143.93.",2020-11-09
0000066570,MSA Safety Inc,MSA,0001547529,Blanco Steven C. Sr.,1000 CRANBERRY WOODS DRIVE,,CRANBERRY WOODS TOWNSHIP,PA,16066,,,1,,,Vice President,,"id=""F2"">Share price on this transaction ranged from $141.80 to $141.89.",2020-11-09
0000066570,MSA Safety Inc,MSA,0001547529,Blanco Steven C. Sr.,1000 CRANBERRY WOODS DRIVE,,CRANBERRY WOODS TOWNSHIP,PA,16066,,,1,,,Vice President,,"id=""F3"">Share price on this transaction ranged from $142.00 to $142.85.",2020-11-09
0000732712,VERIZON COMMUNICATIONS INC,VZ,0001578926,Skiadas Anthony T,VERIZON COMMUNICATIONS INC.,1095 AVENUE OF THE AMERICAS,NEW YORK,NY,10036,,0,1,0,0,SVP & Controller,,"id=""F1"">Each share of phantom stock is the economic equivalent of a portion of one share of common stock and is settled in cash.  The shares of phantom stock become payable upon events established by the reporting person in accordance with the deferred compensation plan.",2020-07-23
0000732712,VERIZON COMMUNICATIONS INC,VZ,0001578926,Skiadas Anthony T,VERIZON COMMUNICATIONS INC.,1095 AVENUE OF THE AMERICAS,NEW YORK,NY,10036,,0,1,0,0,SVP & Controller,,"id=""F2"">Includes phantom stock acquired through dividend reinvestment.",2020-07-23
0000740260,"Ventas, Inc.",VTR,0001531510,Probst Robert F,353 N. CLARK STREET,SUITE 3300,CHICAGO,IL,60654,,0,1,0,0,EVP and CFO,,"id=""F1"">Represents shares withheld to pay taxes on the vesting of restricted stock units granted on January 18, 2017 under the Ventas, Inc. 2012 Incentive Plan (the ""Plan"").  Such vested units are payable solely in common stock of the Issuer and subject to the terms of the Plan.",2020-01-18
0000740260,"Ventas, Inc.",VTR,0001531510,Probst Robert F,353 N. CLARK STREET,SUITE 3300,CHICAGO,IL,60654,,0,1,0,0,EVP and CFO,,"id=""F2"">As of January 18, 2020, Reporting Person owns options to purchase an aggregate of 346,140 shares of Issuer's common stock.",2020-01-18
0000748592,NTN BUZZTIME INC,NTN,0001710390,Simtob Richard Isaac,"1800 ASTON AVE., SUITE 100",,CARLSBAD,CA,92008,,1,0,0,0,,,"id=""F1"">This restricted stock grant was issued to the reporting person under the NTN Buzztime, Inc. 2019 Performance Incentive Plan and pursuant to the NTN Buzztime, Inc. Non-Employee Director Compensation Policy in lieu of the annual retainer earned by the reporting person in his capacity as a non-employee director of the issuer with respect to the quarter ended December 31, 2019. This restricted stock grant was fully-vested on the date of grant.",2019-12-31
0000748592,NTN BUZZTIME INC,NTN,0001710390,Simtob Richard Isaac,"1800 ASTON AVE., SUITE 100",,CARLSBAD,CA,92008,,1,0,0,0,,,"id=""F2"">Owned by minor child.",2019-12-31
0000793733,SKYWEST INC,SKYW,0001546254,Siegfried Meredith R.,444 SOUTH RIVER ROAD,,ST GEORGE,UT,84790,,1,0,0,0,,,"id=""F1"">Shares issued pursuant to the SkyWest, Inc. Long-Term Incentive Plan.",2020-02-04
0000897802,"SPECIAL OPPORTUNITIES FUND, INC.",SPE,0001067621,GOLDSTEIN PHILLIP,60 HERITAGE DRIVE,,PLEASANTVILLE,NY,10570,,1,1,0,0,Chairman and Secretary,,"id=""F1"">The Reporting Person disclaims beneficial ownership of the securities owned by his spouse and this report should not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.",2020-07-15
0000899866,"ALEXION PHARMACEUTICALS, INC.",ALXN,0001792124,Carino Tanisha,"C/O ALEXION PHARMACEUTICALS, INC.",121 SEAPORT BOULEVARD,BOSTON,MA,02210,,0,1,0,0,EVP & CCAO,,"id=""F1"">Award of Restricted Stock Units under the 2017 Incentive Plan.  25% vests on each anniversary of the grant date.",2020-02-28
0000912728,FORWARD AIR CORP,FWRD,0001182297,RUBLE CHRIS C,1915 SNAPPS FERRY ROAD,BUILDING N,GREENEVILLE,TN,37745,,0,1,0,0,Chief Operating Officer,,"id=""F1"">This option vests 33-1/3% each year over a three year period commencing on 2/6/18.",2020-11-27
0000912728,FORWARD AIR CORP,FWRD,0001182297,RUBLE CHRIS C,1915 SNAPPS FERRY ROAD,BUILDING N,GREENEVILLE,TN,37745,,0,1,0,0,Chief Operating Officer,,"id=""F2"">This option vests 33-1/3% each year over a three year period commencing on 2/5/19.",2020-11-27
